

2 **Reduced striatal dopamine transmission as a transdiagnostic** 3 **substrate of psychomotor retardation**

4 Ian Lam Leong,^{1,†} Tsz Huen Ng,^{2,†} Kunal Sen,^{3,†} Ella Burchill,⁴ Harry Costello,⁴ James B.
5 Badenoch,^{5,6} Jan Coebergh,⁷ Robert A. McCutcheon,^{8,9,10} Akshay Nair,^{11,12} Michael Browning,⁸
6 Quentin J. M. Huys,^{4,13} Glyn Lewis,⁴ Andrew Lees,¹⁴ Anthony S. David⁴ and Jonathan P.
7 Rogers^{4,15}

8 [†]**These authors contributed equally to this work.**

9 **Abstract**

10 Psychomotor retardation, defined as generalised slowing of movement and speech, is a feature of
11 several neurological and psychiatric disorders. In this review, we discuss the hypothesis that
12 reduced striatal dopaminergic transmission is a transdiagnostic substrate for psychomotor
13 retardation underlying the motor features of conditions such as Parkinson's disease, drug-induced
14 parkinsonism, neuroleptic malignant syndrome, catatonia and depression. We examine the
15 evidence across clinical, epidemiological, neuroimaging, laboratory and therapeutic studies.

16 Parkinsonian disorders share slowed movement and a reduction in verbal output with catatonia
17 and depression. Bradyphrenia, slowed cognitive processing, also occurs in Parkinson's disease and
18 depression. In addition, there are close epidemiological relationships between depression and
19 Parkinson's disease, and between catatonia and neuroleptic malignant syndrome.

20 Neuroimaging studies also generally support the association of psychomotor retardation with
21 reduced dopaminergic transmission, particularly in the dorsal striatum. Cerebrospinal fluid
22 measurement of homovanillic acid (a dopamine catabolite) yields inconsistent results and is very

nonspecific. Parkinson's disease and catatonia generally respond well to dopaminergic medication. In contrast, dopamine antagonists can induce both parkinsonism and catatonia.

Our review is limited by the variability in measurement of psychomotor retardation and difficulty distinguishing between cognitive and motor slowing. It is also likely that other neurotransmitters, such as GABA and serotonin, play an important role in psychomotor speed.

It is possible that dopaminergic deficits in psychiatric disorders represent functional disruptions, in contrast to the structural damage to the substantia nigra in Parkinson's disease. We propose further research be conducted into the effects of levodopa and dopamine agonists in depression with psychomotor retardation. Alternative neuroimaging methods such as PET sequences with shorter imaging protocols and neuromelanin-MRI should also be explored.

Author affiliations:

1 Division of Psychology and Language Sciences, University College London, London, UK,
WC1H 0AP

2 Faculty of Education, University of Hong Kong, 999077 Hong Kong

3 Faculty of Life Sciences, University College London, London, WC1E 6BT, UK

4 Division of Psychiatry, University College London, London, WC1H 0AL, UK

5 Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience,
King's College London, London, SE5 8AF, UK

6 South London and Maudsley NHS Foundation Trust, London, SE5 8AZ, UK

7 Ashford St Peter's Hospital and St George's Hospitals, Ashford, TW15 3AA, UK

8 Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK

9 Oxford Health NHS Foundation Trust, Oxford, OX3 7JH, UK

10 Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's
College London, London, SE5 8AF, UK

11 Department of Neurology, St. George's University Hospitals NHS Foundation Trust, London,
SW17 0QT, UK

12 Department of Neurology, City St George's University of London, London, SW17 0RE, UK

13 Max Planck UCL Centre for Computational Psychiatry and Ageing Research, Department of
Imaging Neuroscience, Queen Square Institute of Neurology, University College London,
London, WC1N 3BG, UK

14 Reta Lila Weston Institute of Neurological Studies, Queen Square Institute of Neurology,
University College London, London, WC1N 3BG, UK

15 Department of Neuropsychiatry, National Hospital for Neurology and Neurosurgery, London,
WC1N 3BG, UK

Correspondence to: Dr Jonathan Rogers

Division of Psychiatry, University College London, 20 Bedford Way, London, WC1H 0AL, UK

E-mail: jonathan.rogers@ucl.ac.uk

Running title: Dopamine and psychomotor retardation

Keywords: basal ganglia; striatum; movement disorders; bradykinesia; cognitive slowing

Introduction

Psychomotor retardation (PMR) is a generalised slowing of movement and speech.^{1,2} The concept describes difficulties in initiation and maintenance of movements as well as differences between internally and externally generated thoughts or movements.³⁻⁵ Assessment of PMR takes into account an individual's age, culture, baseline activity and environmental factors, such as temperature.

Patients with a range of psychiatric and neurological conditions present with PMR, but the term has been particularly associated with depression, especially melancholic depression.^{6,7} Given that as few as 27% of patients with depression experience remission with untargeted first-line treatment,⁸ there is an urgent need to identify why certain individuals respond to particular treatments. Uncovering transdiagnostic mechanisms for PMR could provide clinicians with novel therapies for depression and other conditions featuring PMR by repurposing medications effective in PMR for other disorders.

Central to the neuroanatomy of voluntary movement are thought to be the cortico-striato-thalamocortical circuits, particularly those involving the dorsal striatum, although the distinction from the ventral striatum is not entirely clear either in terms of cytoarchitecture or histochemistry.⁹ Structural and functional imaging, however, attest to a gradient from medial to lateral and from rostral to caudal in terms of projections from the cortex,¹⁰ which corresponds to a ventral striatum that serves limbic areas of cortex, as opposed to a dorsal striatum serving sensorimotor and associative areas.⁹ The dorsal striatum is in turn anatomically segregated by the internal capsule into the putamen and caudate (Figure 1A). Projections from the sensorimotor cortex converge on the dorsolateral putamen and the lateral caudate nucleus, while association cortex projects to the head of the caudate and the more ventromedial putamen (Figure 1C).^{11,12}

The mechanisms involved in programming voluntary movement are considered to involve the balance of the direct and indirect pathways of the basal ganglia. In the direct pathway, glutamate is released at the striatum, activating inhibitory GABAergic medium spiny neurons projecting to the internal globus pallidus and substantia nigra pars reticulata.^{13,14} This causes disinhibition of thalamic glutamatergic neurons that project back to the cortex and of brainstem motor regions (specifically the midbrain locomotor region and the pedunculopontine tegmental nucleus), which are critical to posture and locomotion.^{13–16} In the indirect pathway, striatal GABA-ergic activity reduces the GABA output of the external globus pallidus, disinhibiting the glutamatergic neurons of the subthalamic nucleus, which excite the internal globus pallidus and substantia nigra pars reticulata.^{13,14} This increases inhibition of the thalamic neurons projecting to the cortex, reducing motion.^{13–15} Dopamine has a crucial modulatory role in both the direct and indirect pathways. Dopamine D₁ receptors (D₁Rs) are expressed at higher levels on direct pathway striatal neurons and have an excitatory effect, whereas D₂ receptors (D₂Rs) have greater expression on indirect

pathway striatal neurons and have an inhibitory effect.¹⁵ A reduction in striatal dopaminergic transmission would thus increase the activity of the indirect pathway whilst decreasing activity in the direct pathway, having a dual effect of inhibiting the initiation and speed of movement. The bradykinesia of Parkinson's disease is therefore – in simple terms – conceived as overactivity of the indirect pathway relative to the direct pathway, although more complex models are being developed.¹⁷

Reduced striatal dopaminergic transmission is present in Parkinson's disease due to loss of dopaminergic neurons in the substantia nigra pars compacta.¹⁸ However, a similar functional disturbance of striatal dopamine signalling has separately been proposed to be present in catatonia,¹⁹ neuroleptic malignant syndrome,²⁰ drug-induced parkinsonism²¹ and in the pathophysiology of depression with PMR.²² In the cognitive domain, Daniel Rogers et al.²³ proposed that bradyphrenia (slowed cognitive processing) in Parkinson's disease and PMR in depression both involve dopaminergic dysfunction, based on a study using a computerised test showed similarities between the two. Lately, Hinkle and Pontone²⁴ have also suggested that catatonia be considered “psychiatric parkinsonism”, based on recent neuroimaging evidence.

In this paper we present the hypothesis that reduced dopaminergic transmission in the striatum (particularly the dorsal striatum) is a transdiagnostic mechanism underlying PMR, using evidence from clinical features, epidemiology, laboratory studies and neuroimaging, as well as response to dopaminergic treatments. Integrating findings from these research modalities and relating them to developments in cognitive neuroscience, we discuss how the theory applies to conditions as diverse as Parkinson's disease, drug-induced parkinsonism, neuroleptic malignant syndrome, catatonia, depression and obsessional slowness.

Clinical Presentation

Overlapping terminology is used to describe slowed movement and cognition in neurology and psychiatry. We present some of the commonly used terms in Table 1.

Before addressing the issue of a transdiagnostic substrate for PMR, we will examine the similarities (and differences) in clinical presentation between Parkinson's disease, where the role of dopamine is established, and other conditions where it is more speculative. Reduced dopaminergic transmission in the dorsal striatum leads to some of the cardinal motor signs of Parkinson's disease, specifically bradykinesia (slowness, with progressive decrement in amplitude and speed of self-initiated movement) and rigidity,²⁵ although its role in tremor is probably more complex.²⁶ Speech in Parkinson's in some ways parallels the bradykinesia, in that there is a delayed onset,^{27,28} but rapid and hesitating speech may also occur,²⁹ mirroring the festinant parkinsonian gait, consisting of a progressive shortening of step length.³⁰

Bradykinesia is not specific to Parkinson's disease, but it is quite specific to reduced striatal dopamine transmission. It is a feature of related parkinsonian syndromes, such as multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration all of which have severe neuronal loss in the pars compacta of the substantia nigra, although it is not uniform and patients with supranuclear palsy seem to lack the decrement present in Parkinson's.^{31,32} Drug-induced parkinsonism – usually due to antagonists of the dopamine D₂ receptor – also has bradykinesia and rigidity as important diagnostic signs.³³ Acutely, antagonists at the D₂ receptor can occasionally trigger neuroleptic malignant syndrome, which consists of the more extreme akinesia, alongside rigidity, altered consciousness, hyperpyrexia and autonomic disturbance.^{34,35} Bradykinesia sometimes also occurs in hyperkinetic disorders such as dystonia, chorea, and Huntington's disease,³⁶ although it should be noted that Huntington's disease has a different dopaminergic mechanism driven by the selective degeneration of striatal medium spiny neurons.³⁷

Psychomotor speed in depression is reduced with meta-analytic evidence finding a standardised mean difference in actigraphically measured psychomotor speed of -0.78 (95% CI -0.99 to -0.57) compared to healthy controls.³⁸ Between 25 and 50% of patients with depression exhibit visible PMR³⁹ and it is strongly correlated with depression severity.⁴⁰ The PMR of depression can present very similarly to the bradykinesia of Parkinson's disease, with comparable presentations of a slow gait, hunched posture, expressionless facies alongside slow movement and quiet speech, although usually to a lesser degree.^{41–43} The performance of patients with depression in certain cognitive

tasks appears to be related to their motor slowing.²³ Perhaps an even closer comparison may be made with catatonia, a neuropsychiatric syndrome of various aetiologies, classically consisting of stupor, mutism and behavioural withdrawal.⁴⁴ A comparison of clinical features between Parkinson's disease and catatonia is shown in Table 2, illustrating similarities in muscle tone, speed and quantity of movement, facial expression, freezing episodes and altered mental status. There is an entity of excited catatonia, which may alternate with stuporous states,^{44,45} suggesting that either catatonia is not a pathophysiologically homogeneous state, or that there are rapid fluctuations in the neurochemistry of the basal ganglia. Importantly, the onset of catatonia tends to be subacute, unlike the gradual onset seen in Parkinson's disease.

We have shown that some neurological and psychiatric conditions share PMR. Motor slowing also appears to be closely related to mental processes at the level of analysis of the individual condition. In Parkinson's disease, bradykinesia is strongly correlated with bradyphrenia – slowed cognitive processing.⁴⁶ There is, moreover, a correlation between bradykinesia and some of the affective dimensions of Parkinson's disease, specifically anhedonia and apathy.^{47–52} Anhedonia and apathy are both thought to be related to the dopaminergic deficits, although the specific localisation is possibly more likely to be in mesocorticolimbic pathways, rather than the nigrostriatal projections thought to be responsible for bradykinesia.^{49,53–55} Cognition is also likely to be relevant to these affective states, as executive dysfunction is closely related to apathy.^{56,57} However, while bradykinesia is correlated with anhedonia and apathy, these are phenomenologically distinct concepts and do not always coexist.^{58,59}

In psychiatric conditions as well, there is evidence that PMR is closely linked to the affective state. In obsessional slowness, a severe form of obsessive-compulsive disorder, there is difficulty initiating voluntary action and often severely slowed movement.⁶⁰ In depression, PMR correlates with anhedonia,⁶¹ mirroring the association seen with bradykinesia in Parkinson's disease.

In summary, the bradykinesia seen in Parkinson's disease and other neurological movement disorders shows phenomenological similarities to the PMR of various psychiatric conditions,

although subtler aspects such as the motor decrement are not clearly present in psychiatric conditions. There is also a relationship between PMR and states such as anhedonia and apathy, which are thought to be related to reduced dopamine transmission.

Epidemiology

There is epidemiological evidence to suggest that depression is related to the development of parkinsonian disorders. Two meta-analyses have found an increased risk of subsequent Parkinson's disease in patients with depression, with an odds ratio (OR) of 2.04 (95% CI, 1.02–4.08) and relative risk (RR) of 2.20 (95% CI, 1.87–2.58) respectively.^{62,63} Intervals of between 2 and 16 years between onset of depression and Parkinson's disease diagnosis have been reported.⁶² The results of a recent Mendelian randomisation study suggest that depression has a causal role in the development of Parkinson's disease.⁶⁴ The largest genome-wide association study of depression to date found that one of the genes with the strongest evidence was the dopamine receptor D₂ (*DRD2*) gene.⁶⁵ There is some evidence that PMR may constitute a genetically distinct form of depression,⁶⁶ but we are not aware of studies that have investigated whether this group is particularly at-risk for developing Parkinson's disease.

As a rarer disorder, evidence for catatonia is weaker. Catatonia has occasionally been reported to co-occur with Parkinson's disease, dementia with Lewy bodies and progressive supranuclear palsy.^{67–76} In some cases, catatonia has been reported in the context of Parkinson's disease after withdrawal of pro-dopaminergic medications.^{76,77} Parkinsonism and catatonia have also been noted to co-occur in certain genetic syndromes, including in Rett syndrome⁷⁸ and in a patient with variants of the *SHANK3* and *SYNJ1* genes.⁷⁹ These reports are suggestive but by no means conclusive.

Catatonia is, however, convincingly linked to the development of neuroleptic malignant syndrome. Catatonia may co-exist with neuroleptic malignant syndrome and some authors have suggested that neuroleptic malignant syndrome is merely a subtype of malignant catatonia.⁸⁰ Even if one does not accept this contention – and there are features such as diaphoresis, rigor,

fever and tremor that are relatively specific to neuroleptic malignant syndrome⁸¹ – the epidemiological relationship between the two conditions is compelling. Catatonia has been found to precede,⁸² co-exist with⁸³ and follow neuroleptic malignant syndrome.^{84–86} Among 1719 patients with schizophrenia, one study found that the odds ratio for catatonia was 87.0 (95% CI 25.3 – 462.8) if neuroleptic malignant syndrome was present.⁸⁷ There also appears to be a spectrum between antipsychotic-induced catatonia and neuroleptic malignant syndrome.⁸⁸

In summary, depression is robustly linked to the subsequent development of Parkinson's disease. Case reports and series suggest a relationship between catatonia and various parkinsonian disorders, but there is now convincing epidemiological evidence of a relationship to neuroleptic malignant syndrome.

Laboratory Evidence

Homovanillic acid (HVA) is the end-product of dopamine metabolism and can be measured in cerebrospinal fluid (CSF) as a biomarker of central dopaminergic activity.⁸⁹ HVA is reduced in Parkinson's disease^{90–92} and correlates with disease progression. A small study of neuroleptic malignant syndrome also found reduced HVA, which persisted beyond recovery, suggesting an underlying hypo-dopaminergic predisposition.⁹³

Studies on whether HVA is reduced in individuals with depression compared to healthy controls have yielded inconsistent results,^{94–97} as have those comparing depressed patients with and without a melancholic subtype.^{98,99} Two studies have examined the relationship between PMR and HVA in patients with depression, finding no correlation.^{100,101} In one study, patients with depression and PMR had lower CSF HVA concentrations than healthy controls and those with depression without PMR, but the numbers were small and did not reach statistical significance.¹⁰⁰ One study has found that HVA levels were positively correlated with psychomotor activity, but this included patients with depression and mania, so it is possible that the finding was driven by the latter group.¹⁰²

In catatonia, one study found increased HVA levels relative to healthy controls.¹⁰³ The same group found no relationship between an excited or retarded catatonia phenotype and HVA levels, although lorazepam responders appeared to have higher levels.¹⁰⁴

Before trying to interpret these findings, it is worth providing some caveats about the measurement of CSF HVA. Such measurement is neuroanatomically non-specific; that is, it does not allow us to ascertain the extent of dopamine metabolism in a particular part of the brain. Secondly, it is temporally non-specific; that is, it is unable to capture rapid fluctuations in dopamine metabolism, such as those that may occur during phasic release associated with certain behavioural responses.¹⁰⁵ This may be particularly relevant to psychiatric disorders, where there may be a functional dopaminergic deficit without the corresponding structural pathology in the substantia nigra that is present in Parkinson's disease.

Evidence from CSF studies strongly supports the role of dopamine in Parkinson's disease. Evidence for other conditions is much weaker, but the limitations of the method and the small studies conducted do not contradict our hypothesis. The studies do suggest that at some level the effect in depression and catatonia is different or at least more transient than in Parkinson's disease. Northoff et al.¹⁰³ hypothesised that the elevated HVA levels in patients with catatonia are due to increased mesolimbic dopaminergic transmission, which in turn downregulates nigrostriatal transmission, causing catatonia. Whilst this is largely speculative, it is compatible with the neuroimaging evidence we present later in this paper.

Neuroimaging

Functional neuroimaging provides substantially more anatomical specificity than measurements of dopamine metabolites in CSF. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) enable the quantification of dopaminergic transmission in the brain, as illustrated in Figure 2. In [¹⁸F]-FDOPA PET, radiolabelled DOPA is administered to participants and is subsequently converted by aromatic L-amino acid decarboxylase (AADC) to [¹⁸F]-dopamine, which is sequestered within synaptic vesicles. Modelling of this uptake allows the

1 calculation of the influx rate constant, K_i , that serves as a measure of presynaptic dopamine
2 synthesis capacity.¹⁰⁶

3
4 In Parkinson's disease, there is a convergence of both postmortem and neuroimaging studies
5 showing that most degeneration in the nigrostriatal pathway preferentially affects the more
6 caudolateral regions of the putamen.¹⁰⁷ Significant reductions in putaminal [^{18}F]-FDOPA uptake
7 and putaminal [^{11}C]-nomifensine ([^{11}C]-NMF) binding (representing nigrostriatal nerve terminal
8 reuptake site density¹⁰⁸) correlate with the severity and lateralisation of bradykinesia and
9 rigidity.^{109–112} Relative to healthy controls, putaminal [^{123}I]-FP-CIT uptake levels (which represent
10 density of the dopamine transporter) in patients with Parkinson's disease correlate with the mean
11 speed and amplitude of finger tapping, while caudate uptake levels correlate with mean
12 amplitude.¹¹³

13
14 In early Parkinson's disease, initial upregulation of striatal post-synaptic D_2 receptors (D_2R) shown
15 by [^{11}C]-raclopride-PET and [^{123}I]-IBZM-SPECT (both of which bind to dopamine D_2/D_3
16 receptors) has been interpreted as a compensatory mechanism for pre-synaptic dopaminergic nerve
17 terminal loss, followed by downregulation approximately four years following motor symptom
18 onset.¹¹⁴ Though it remains difficult to ascertain whether downregulation results from disease
19 progression or medication,¹¹⁵ consistent observations of higher striatal D_2R binding contralateral
20 to predominant motor features suggest that the initial upregulation is a temporary compensatory
21 response to dopamine depletion resulting from pre-synaptic degeneration in early Parkinson's
22 disease.¹¹⁴ This is in accord with the inverse correlation observed between [^{18}F]-FDOPA uptake
23 and [^{11}C]-raclopride binding in levodopa-naïve Parkinson's disease patients.¹¹⁶

24
25 Various lines of converging evidence suggest that a dopaminergic deficit in the sensorimotor
26 striatum is specific to bradykinesia, rather than explanatory for all features of Parkinson's disease.
27 An [^{18}F]-FDOPA study found that uptake in the caudate nucleus was negatively associated with
28 measures of executive functioning.¹¹⁷ Caudate pre-synaptic dopaminergic nerve terminal and
29 transporter dysfunction correlates with slower cognitive speed and impaired verbal fluency.^{118,119}

Bradyphrenia appears to be correlated with [^{123}I]-FP-CIT uptake in the head of the caudate.¹²⁰ This is consistent with neuropathological findings showing reduced D1 receptor density in the caudate correlating with cognitive impairment.¹²¹ Anhedonia appears to involve both caudate and putaminal regions of the dorsal striatum in terms of DAT binding.¹²² Using [^{11}C]RTI-32 PET, a marker of dopamine and noradrenaline transporter binding, Remy et al. found a relationship between depression in Parkinson's disease and lower binding in the locus coeruleus and the ventral striatum.¹²³ The pathophysiology of the parkinsonian tremor does not appear to be primarily due to a dopaminergic deficit, nor does it correlate well with bradykinesia and rigidity.^{124–126} Thus, cognitive symptoms, affective symptoms and even tremor do not appear to depend specifically on the sensorimotor striatum in Parkinson's disease in the way that bradykinesia does.

In parkinsonism secondary to dopamine antagonists, decreased [^{123}I]-FP-CIT binding in the putamen (a measure of dopamine transporter availability¹²⁷) is present in a proportion of individuals¹²⁸ and predicts levodopa response and parkinsonian symptom progression,¹²⁹ with reduced putaminal [^{18}F]-FDOPA uptake observed in cases of continued or deteriorating parkinsonism post-withdrawal.¹³⁰ This suggests that parkinsonism secondary to dopamine antagonists sometimes occurs in an at-risk population with subclinical pre-synaptic nigrostriatal dysfunctions.¹³¹ In neuroleptic malignant syndrome, [^{123}I]-IBZM-SPECT (a measure of post-synaptic D₂ receptor density¹³²) reveals near-absent basal ganglia D₂R binding of the ligand in the acute phase,¹³³ indicating dopamine antagonist occupancy of post-synaptic D₂R as a mechanism for reduced dopaminergic transmission associated with motor impairments.

Studies on catatonia mainly concentrate on pre-synaptic function, with limited data concerning post-synaptic D₂Rs.¹³⁴ Three [^{18}F]-FDOPA-PET studies of individuals with psychosis have each included a single patient with catatonia and have found decreased putaminal and caudate uptake in patients relative to other patients with schizophrenia and healthy controls,^{135–137} and comparable caudate Ki values to Parkinson's disease,¹³⁸ suggesting a similar presynaptic hypodopaminergia. Importantly, unlike D₂R ligands, [^{18}F]-FDOPA does not appear to be modulated by D₂R antagonists.¹³⁹ However, it is not clear whether such observations represent a transient state or a longer-term trait. One small study of five patients suggested that dopaminergic abnormalities – at

1 least presynaptically – are transient: five older women with catatonia and depression underwent a
 2 DAT-SPECT, which uses [^{123}I]-FP-CIT-SPECT to ascertain the density of DAT in the presynaptic
 3 terminal, finding reduced binding in the striatum, which improved after treatment with
 4 benzodiazepines or ECT.¹⁴⁰ One possible interpretation is that the reduction in dopamine
 5 transporter (DAT) might be a compensatory response to reduced synaptic dopamine levels.

7 In depression, patients with motor retardation show lower left caudate [^{18}F]-FDOPA uptake,¹⁴¹
 8 suggesting impaired presynaptic dopamine synthesis and storage. Studies investigating alterations
 9 in striatal DAT binding in depression have obtained mixed results.^{142,143} It should be noted that
 10 these studies did not specifically examine the relationship between DAT binding and PMR, and
 11 that the inconsistent findings may be due to the heterogeneity of depressed subjects included and
 12 medication effects. Studies of postsynaptic dopaminergic function in patients with depression and
 13 PMR have consistently found an increased binding of ligands to D₂ receptors compared to patients
 14 with depression without PMR, with studies examining striatal [^{123}I]-IBZM binding¹⁴⁴ and
 15 putaminal [^{11}C]-raclopride binding.¹⁴⁵ Concordantly, increased right striatal [^{123}I]-IBZM binding
 16 correlates positively with reaction or movement time and negatively with verbal fluency.¹⁴⁶ Given
 17 that presynaptic dopamine production is impaired, this may either represent increased availability
 18 of D₂ receptors due to reduced levels of the endogenous ligand, or some compensatory response
 19 to a presynaptic deficit.

21 Overall, neuroimaging evidence supports the hypothesis that reduced dorsal striatal dopaminergic
 22 transmission is associated with psychomotor deficits across conditions. A summary of studies is
 23 included in Table 3, while Figure 1B and 1D provides a visual comparison of studies in Parkinson's
 24 disease and depression. In Parkinson's disease, there is evidence that this is mainly related to the
 25 sensorimotor striatum (predominantly the putamen), but there is insufficient evidence from other
 26 conditions to localise the deficit so precisely. Post-synaptic alterations in depression consisting of
 27 increased binding to D₂Rs parallel the findings in early-stage Parkinson's rather than those in a
 28 later stage of the disease. Data on D₁R binding are sparse, but are perhaps less relevant, given that
 29 available PET studies examining Parkinson's disease patients typically observe no differences in
 30 striatal D₁R binding compared to healthy controls.¹⁴⁷ For Parkinson's disease and PMR in

depression, there is evidence implicating the caudate and putamen, but the role of the ventral striatum has been less well characterised. Evidence for drug-induced parkinsonism, neuroleptic malignant syndrome, catatonia, obsessional slowness and hyperkinetic disorders is less comprehensive and requires further research.

Dopaminergic Treatments

L-DOPA, the immediate precursor of dopamine, is the mainstay of treatment for Parkinson's disease, acting through supplementing deficient dopamine synthesis.¹⁴⁸ Other effective pharmacotherapies include dopamine agonists and monoamine oxidase inhibitors (MAOIs), which inhibit dopamine catabolism.^{149–154} Observational data suggest that dopamine agonists improve motivational symptoms while monoamine oxidase inhibitors improve both depressive and motivational symptoms in Parkinson's.¹⁵⁵ A large randomised controlled trial of the dopamine agonist pramipexole versus placebo in Parkinson's found an improvement in depression that was largely not mediated by improved motor symptoms.¹⁵⁶

Conversely, antipsychotics that act as antagonists at the dopamine D₂ receptor can induce parkinsonism, with typical antipsychotics posing greater risk.²¹ Antipsychotic-induced parkinsonism can be treated with the dopamine agonist rotigotine or amantadine, which enhances dopamine synthesis and release.^{157–159}

Neuroleptic malignant syndrome is an adverse effect of antipsychotic treatment, with typical antipsychotics and higher doses associated with increased risk.^{160,161} There is evidence that the dopamine agonist bromocriptine can be used to treat neuroleptic malignant syndrome,^{162,163} and a case series suggested levodopa may also be beneficial.¹⁶⁴ Discontinuation of pro-dopaminergic medication in patients with Parkinson's disease has been shown to cause neuroleptic malignant syndrome-like symptoms (parkinsonism-hyperpyrexia syndrome).^{165–169}

1 The use of antipsychotics in catatonia is controversial because of a frequent perceived need to treat
2 underlying psychosis and reported benefits in such circumstances.¹⁷⁰ Aside from the risk of
3 inducing neuroleptic malignant syndrome,⁸⁷ antipsychotics can induce or worsen catatonia, with
4 typical antipsychotics posing a greater risk, postulated to be due to their higher affinity for D₂R.⁸⁸
5 Antipsychotics can simultaneously induce catatonia and parkinsonism.¹⁷¹ Clozapine, which has a
6 unique cholinergic mechanism and weak D₂R affinity, may be an exception that is effective in
7 catatonia,^{172,173} with clozapine withdrawal sometimes precipitating catatonia.¹⁷⁴ Conversely,
8 initial evidence from one small human study and two animal models, suggests levodopa may be
9 beneficial for treating catatonia, although worsening psychosis has limited its use.^{175–177} Various
10 case reports also support the use of amantadine and methylphenidate.^{178–181}

12 In depression, there is evidence for benefit in mood from several randomised controlled trials for
13 the dopamine agonist pramipexole,^{182,183} though studies have not investigated PMR as an
14 outcome. There is less evidence that levodopa and amineptine (a dopamine releasing agent and
15 reuptake inhibitor¹⁸⁴) are effective at alleviating PMR in depression.^{22,185–187} Bupropion, a
16 noradrenergic and dopamine reuptake inhibitor, has evidence from numerous clinical trials
17 supporting its superiority to placebo in depression.¹⁸⁸ Interestingly, poor mental processing speed
18 in depression has been shown to be a predictor of strong response to the noradrenergic and
19 dopaminergic reuptake inhibitor, bupropion.^{189,190} Aripiprazole, a dopamine partial agonist, has
20 evidence for augmentation of antidepressant response in treatment-resistant depression, although
21 studies have not examined PMR specifically.¹⁹¹ Inhibitors of monoamine oxidase-A, which reduce
22 reuptake of a range of neurotransmitters including dopamine, are also effective in depression
23 though little is known about predictors of response.¹⁹²

25 Another treatment predominantly used for depression that merits a mention is electroconvulsive
26 therapy (ECT), the use of an electrical stimulus to induce a generalised seizure.¹⁹³ ECT is
27 associated with volumetric increases in the nucleus accumbens and caudate nucleus, correlating
28 with improved PMR in depression.^{194,195} Similarly, a relative increase in metabolism in basal
29 ganglia regions have been detected following.¹⁹⁶ A mean reduction in striatal DAT binding of
30 13.1% and reduced dopamine autoreceptor sensitivity following ECT are observed.^{197,198}

Interestingly, ECT in Parkinson's disease transiently improves motor function, even when patients with prior psychiatric morbidity are excluded.^{199,200} However, the mechanisms of ECT remain poorly understood, likely involving multiple neurotransmitters.^{201,202}

Overall, dopamine antagonists tend to induce and worsen PMR, while it is ameliorated by medications that enhance dopamine transmission, either by increasing dopamine release or inhibiting its breakdown. However, the evidence in catatonia and depression remains preliminary with small sample sizes and a lack of well-conducted clinical trials. A summary of the impact of dopaminergic medications on different neuropsychiatric conditions is shown in Table 4. While it is plausible that ECT acts through dopaminergic mechanisms, there remains a great deal of uncertainty.

Cognitive Neuroscience

We have reviewed the evidence that striatal dopamine transmission plays a transdiagnostic role in PMR, beyond the more established case of Parkinson's disease. The question remains as to whether this is plausible given what we understand about the neurobiology of dopamine transmission in the striatum.

Dopamine has a critical role in self-initiated movement across various brain regions.²⁰³ Rather than directly controlling fine movement kinematics, its influence lies in the initiation and execution of deliberate actions.²⁰⁴ There are transient increases in nigrostriatal dopaminergic neuronal activity that consistently precede movement initiation or acceleration in mice, which correlate with the vigour of future movements.²⁰⁵ Mesolimbic dopaminergic transmission is also key to causal learning through retrospective associations,²⁰⁶ and prediction error calculations.²⁰⁷ The ventral tegmental area's potential downstream effects on the ventral striatum have been increasingly recognised in Parkinson's disease, particularly for non-motor symptoms.²⁰⁸ Considerable evidence indicates the nucleus accumbens as a 'limbic-motor interface' that translates motivation into action.^{209,210}

However, it is the dorsal striatum that is thought to be central in "action-energising" movement. Tonic dopamine levels in the dorsal striatum encode motivational signals that reflect the energetic

cost of movement (i.e. the appropriate allocation of energy to match the demands of the task).²¹¹ Despite similar movement parameters (i.e. trajectory quality, endpoint accuracy, energy expenditure) to healthy controls, patients with Parkinson's disease exhibit slower movement with increased energetic demands,²¹¹ leading to bradykinesia being conceptualised as 'implicit' motor motivation deficits.²¹² In other words, the slow movement observed in Parkinson's disease is due to a lack of motor vigour, rather than an inability to move quickly or a simple speed-accuracy trade-off. Patients prefer slower movements because they are more sensitive to the energetic cost of faster, more demanding movements.²¹³ Similar impairments in depression and schizophrenia suggest that movement speed reflects implicit evaluations of movement energy costs signalled by striatal dopamine.²¹⁴ Additionally, reduced dorsal striatal DAT binding, indicative of pre-synaptic neuronal death, is related to anhedonia and apathy.^{122,215} Considered collectively, motor speed may reflect a paucity of motivational drive.

These findings could reflect how striatal dopaminergic dysfunction affects effort-related decision-making by impairing the evaluation of motor energy costs. In Parkinson's disease, the loss of dorsal striatal dopamine function weakens the connection between motivation and movement gain.²¹⁶ This is consistent with the striatal dopaminergic system's role in reward-based learning, where dopaminergic neurons encode a discrepancy between expected and obtained rewards of an action.²¹⁷ This 'reward prediction error' (RPE) signal effectively guides learning until the reward gain is maximised.²¹⁸ Though these processes have typically been associated with the ventral striatum,²¹⁹ recent evidence implicates the involvement of the dorsal striatum, with the putamen and caudate nucleus potentially implicated in different roles.^{220–222} A gradient in the speed of reuptake of dopamine has been reported from the ventral to dorsal components of the striatum, with the dorsal striatum more sensitive to the temporally precise phasic signals and encoding prediction errors than the ventral striatum.^{223,224} The putamen appears to be important for the encoding and learning of stimulus-action associations,²²⁵ while the caudate nucleus is involved in the encoding of RPEs during goal-directed behaviour.²²⁶ These regions work in parallel to integrate sensorimotor, cognitive and motivational emotion that support action selection and initiation in goal-directed action.^{227–229} Thus, striatal dopamine release signals the value of actions, facilitating both motor learning and the invigoration of actions associated with motivationally significant outcomes, all of which are very relevant to psychiatric conditions such as depression and catatonia.

Beyond effort evaluation, decision-making about movement also involves deliberation, during which the individual evaluates different courses of action over time. Deliberation involves processes such as working memory, rule extraction and outcome prediction. Based on this definition, Pessiglione et al. noted a disrupted temporal uncoupling between mental deliberation and motor execution in unmedicated Parkinson's disease patients relative to healthy controls, which was reversed by levodopa but not by subthalamic nucleus deep brain stimulation.²³⁰ However, as this study was not accompanied by molecular imaging, the precise site and mechanisms of dopamine depletion remain unclear. The findings also led to speculation that the loss of functional segregation between basal ganglia circuits may explain the loss of temporal uncoupling between deliberation and execution, leading to decision-related hesitations being expressed as movements.

Notably, the striatal subregions may perform different functions depending on the types of stimulus inputs (e.g. conditioned versus unconditioned, external versus internal), and the parameters of motor control (e.g. large- versus small-scale, locomotion versus manipulation) being governed.²³¹ Thus external sensory stimuli can be effective in facilitating gait initiation in Parkinson's patients with freezing of gait,^{232–234} particularly visual cues in improving gait speed.^{235,236} Interestingly, it has been shown that akinetic Parkinson's patients can show a sudden temporary ability to move in situations of intense emergency, so-called *kinesia paradoxa*.²³⁷ These findings suggest that difficulties in movement initiation could be overcome by altering the sensory input, and that the fundamental impairment in Parkinson's disease may be rooted in the execution of actions in response to the individual's intentions.²³⁸ Catatonic signs can similarly fluctuate within an illness episode.^{239,240}

There is also a reduced capacity to switch between different motor programs within a broader motor plan in Parkinson's disease.²⁴¹ Specifically, impairments in sequential and simultaneous movements are more pronounced compared to individual movements.²⁴² Therefore, the inability to switch between motor plans may be a process underlying the reduced capacity to generate spontaneous voluntary action and the pronounced slowness in Parkinson's disease.

Relatedly, the nigrostriatal network may be implicated in the initial learning of sequential motor tasks and the memory processes enabling recall of learned motor sequences. Specifically, striatal dopaminergic transmission may be involved in the acquisition of predictive movement sequences and the efficient predictive retrieval of succeeding movements to form complete goal-oriented action sequences in monkeys.²⁴³ Moreover, there is evidence of striatal dopamine release during performance of a motor sequential learning task in humans. Measurements of dopamine D₂ receptor availability by [¹¹C]-raclopride have revealed that activation in the left putamen and right caudate is associated with response selection and execution, while activation in the left caudate is associated with detecting contextual changes.^{244,245} Taken together, these findings may be interpreted as a plausible explanation for the difficulties in motor plan switching experienced by Parkinson's patients, and also aligns with the suggestion that striatal processing enables the "chunking" of sequential acts into performance units.²⁴⁶

In summary, it is possible that dysfunction of dopaminergic transmission in the dorsal striatum (with stronger motor correlates) more directly affects movement parameters such as frequency, speed and control. In contrast, dysfunction in the ventral striatum (with stronger RPE correlates) may influence movement indirectly by affecting cognitive functions like motivation, decision-making and learning. Therefore, it may be that the striatal subregions operate hierarchically to contribute to PMR. This view may be supported by the temporal gradient in dopamine degeneration observed in Parkinson's disease, with the dorsal striatum being affected in early stages of the disease, progressing to the ventral striatum in later stages of the disease.^{247,248} However, it would be an oversimplification to associate the dorsal striatum solely with motor functions and the ventral striatum strictly with limbic or motivational functions. Ventral striatal dopaminergic depletions still impact motor parameters by reducing the overall frequency and speed of various activities. Although further research is needed to clarify the roles of these striatal subregions, dopamine transmission remains a central mechanism underlying both motor and motivational control.

Discussion

In this review, we have synthesised the evidence that reduced striatal dopamine transmission is a transdiagnostic substrate for PMR. The overlapping clinical features across conditions imply striatal dopamine as a common substrate for PMR. Epidemiological evidence indicates that transdiagnostic PMR in clinical populations may result from predisposed dopaminergic dysfunction or antidopaminergic medication effects. Molecular neuroimaging and laboratory evidence mainly associate reduced dorsal striatal transmission with PMR. Dopaminergic medication appears effective in various conditions with PMR.

Mesolimbic dopaminergic transmission is key to causal learning through retrospective associations,²⁰⁶ and prediction error calculations.²⁰⁷ The ventral tegmental area's potential downstream effects on the ventral striatum are increasingly recognised in Parkinson's disease, particularly in relation to cognitive and affective symptoms.²⁰⁸ Considerable evidence indicates the nucleus accumbens as a 'limbic-motor interface' that translates motivation into action.^{209,210} However, dorsal striatal dopaminergic activity remains central for 'action-energising' movement. Motor speed may reflect a reduction in motivational drive due to reduced striatal dopamine signalling.

Although this review has focused on dopamine, it would be an oversimplification to attribute the full spectrum of motor features of a diverse range of conditions to a single neurotransmitter. In Parkinson's disease, while it is accepted that non-dopaminergic mechanisms are central to non-motor symptoms,²⁴⁹ it is also clear that other neurotransmitters are involved in motor symptoms, although their role is probably less straightforward than that of dopamine. PET studies have found that serotonergic terminals are depleted early in the course of Parkinson's disease, supporting findings of older postmortem studies,²⁵⁰ but serotonin transporter availability does not seem to correlate with motor symptoms.²⁵¹ While the serotonin receptor agonist *meta*-chlorophenylpiperazine (*m*CPP) results in reduced locomotor activity in rodents,^{252,253} in healthy humans this effect appears to be driven primarily by cognitive slowing rather than a direct motor effect.²⁵⁴ Cholinergic dysfunction has also been implicated in the motor symptoms of Parkinson's

disease, but this is primarily in posture and freezing of gait, rather than in bradykinesia.²⁵⁵ Cortical GABA levels – as measured in magnetic resonance spectroscopy – do not appear to differ between individuals with Parkinson’s disease and healthy controls, but one study did find an inverse correlation between GABA in the motor cortex and motor symptoms.²⁵⁶

In catatonia, there is evidence both from the effectiveness of benzodiazepines²⁵⁷ and from SPECT imaging showing a reduced density of GABA-A receptors in the left sensorimotor cortex²⁵⁸ that GABA is also central to the pathophysiology. It is increasingly recognised that there are collections of neurons in the human central nervous system that can co-release both GABA and dopamine.²⁵⁹ In depression, it is likely that a range of monoamines are relevant²⁶⁰ and a reciprocal relationship between serotonin and dopamine release in the substantia nigra is observed.²⁶¹ In ECT, glutamate and GABA release mediated through serotonin receptor sensitisation modulates dopamine function.²⁶² A pivotal role for dopamine therefore is not to the exclusion of other neurotransmitters and there are clear relationships in the striatum between dopamine and transmitters including acetylcholine, glutamate and GABA. However, we focus on dopamine because this seems to be where the preponderance of evidence is and where there is clearest transdiagnostic relevance.

While PMR may be associated with dorsal striatal dopamine transmission downregulation, it is less clear – or less straightforward – that increased striatal dopamine transmission is linked to psychomotor agitation, as evidenced by neuroimaging findings and clinical observations of co-existing PMR and psychomotor agitation.²⁶³

One limitation to our findings is the heterogeneity of measurement of PMR in the evidence underpinning our review.⁶ Distinguishing cognitive from motor variables is challenging, as it introduces confounders such as executive functions, memory and attention.^{7,264} PMR scales, despite good psychometric properties, are susceptible to bias due to unnaturalistic settings.^{7,38} Actigraphy, measuring activity level over longer periods, provides a more naturalistic and objective alternative but may not correlate with other behaviours.³⁸ Advances in instrumentation

and measurement modalities used in conjunction may enhance ecological validity and identify underlying brain circuitry.²⁶⁵

One important implication from this review is that current diagnostic classifications of psychiatric disorders may be grouping together disorders that are highly heterogeneous in their pathophysiology. Depression may or may not feature PMR. Catatonia may present with a stuporous-retarded phenotype, but it may equally in current classifications present with an excited-agitated phenotype.^{2,44,266} We propose that future studies of psychiatric disorders with prominent motor phenotypes consider restricting their samples to a certain phenotype or stratifying the analysis by that phenotype. Given the heterogeneity of depression and low response rates to first-line therapy, the need for new and effective therapeutic interventions cannot be understated. Further studies are required to determine if PMR predicts response to dopaminergic antidepressants (e.g. bupropion and monoamine oxidase inhibitors). Although initial evidence suggests levodopa and dopamine agonists alleviate PMR in depression, recent larger studies have been retracted due to methodological issues.^{267,268} Based on our research, we propose re-attempting these studies and conducting larger trials with dopamine agonists in selected populations by motor phenotype as a way of avoiding grouping patients with divergent pathophysiology. This approach may also benefit akinetic catatonia, as some evidence indicates the efficacy of levodopa and methylphenidate.^{175–177,269} ECT is recommended for patients with PMR, and/or resistant to pharmacological treatment, but is underused due to stigma.^{270–272} Further studies about its mechanism could dispel misconceptions, and dopamine transmission is a promising candidate.

Another implication concerns the imaging modalities we should consider employing in research on neuropsychiatric disorders. In Parkinson's disease, we can localise bradykinesia quite precisely to the dorsolateral striatum, though in other conditions there is less certainty and anatomical specificity. Considering the difficulty of obtaining consent for invasive procedures and having severely unwell patients remain still in a scanner for prolonged periods, future research could explore alternative imaging methods. One option may be ¹⁸F-(*E*)-*N*-(3-iodoprop-2-enyl)-2 β -carbofluoroethoxy-3 β -(4'-methyl-phenyl) nortropane ([¹⁸F]FE-PE2I)-PET, which shows comparable sensitivity and specificity with superior striatal DAT specificity to [¹²³I]FP-CIT-

SPECT.^{273,274} Its faster kinetics enable shorter intervals between injection and imaging ([¹⁸F]FE-PE2I: ≤ 20 minutes, [¹²³I]FP-CIT: ~30 minutes) and shorter static imaging protocols (16.5-42 minutes).^{273,275} There is also a fast [¹⁸F]DOPA PET imaging protocol,²⁷⁶ which may be better tolerated by unwell patients. Another option is neuromelanin MRI (NM-MRI), increasingly validated as a non-invasive, cost-effective measure of pre-synaptic dopaminergic neuron density and function, although it is less able to capture transient states.²⁷⁷ Neuromelanin (NM) accumulates in the midbrain nuclei throughout the lifespan,²⁷⁸ reflecting a more stable marker of dopamine synthesis compared to the state-specific data from PET/SPECT.²⁷⁹ NM-MRI signals correlate with PET/SPECT measures of striatal dopamine terminal loss,^{280–282} dorsal striatal dopamine release²⁸³ and putaminal dopamine synthesis in Parkinson's disease,²⁸⁴ showing decreased NM signal intensity in the substantia nigra pars compacta compared to healthy controls.^{285–288} However, its applicability in other conditions requires further research. If reduced striatal dopamine transmission accounts for PMR across conditions, similar decreases in NM signal intensity and striatal DAT binding would be expected in catatonia and some forms of depression if performed when the patient is unwell. It is not clear whether the pathology in the substantia nigra in Parkinson's disease is mirrored in other conditions featuring psychomotor retardation, which may entail functional rather than structural deficits.

The evidence examined in this narrative review generally supports reduced dorsal striatal dopamine transmission as a transdiagnostic substrate for PMR across various neurological and psychiatric conditions. That is, reduced dopamine transmission could contribute to the pathophysiology of PMR. While current evidence is insufficient to conclusively define anatomical and mechanistic specificities, we suggest that pre-synaptic dysfunction in dopamine storage and reuptake in the dorsal striatum affects downstream neurotransmission, resulting in PMR. However, while the role of dopamine in Parkinson's disease is compelling, there are substantial gaps in the literature for psychiatric conditions, which could be filled by further neuroimaging and a clinical trial of a dopaminergic medication in patients with depression and PMR.

Striatal dopamine should be considered alongside other interacting neurotransmitters, with further investigation needed into medication action sites and the anatomical and mechanistic specifics of

striatal transmission. Future research should move beyond static models to explore striatal dopamine's role in PMR as part of a dynamic, complex system with nuanced roles of striatal subregions and the interplay with other neurotransmitter systems.

Funding

JPR was funded by Wellcome (220659/Z/20/Z) and NIHR (CL-2023-18-002). ILL and THN were supported by the Laidlaw Foundation.

RAM's work is funded by a Wellcome Trust Clinical Research Career Development Fellowship (224625/Z/21/Z)

MB was supported by the Office for Life Sciences and the National Institute for Health and Care Research (NIHR) Mental Health Translational Research Collaboration, hosted by the NIHR Oxford Health Biomedical Research Centre and by the NIHR Oxford Health Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health and Social Care.

Competing interests

Jonathan Rogers reports research funding from Wellcome and NIHR; royalties from Taylor & Francis; payment for reviewing from Johns Hopkins University Press; and speaker fees from the Alberta Psychiatric Association, Grey Nuns Hospital (Edmonton), Infomed Research & Training Ltd., North East London NHS Foundation Trust and Vanderbilt University Medical Center. He is a Council member for the British Association for Psychopharmacology and a member of the Medical Advisory Board of the Catatonia Foundation. He conducts expert witness work. RAM has received speaker/consultancy fees from Boehringer Ingelheim, Janssen, Karuna, Lundbeck, Newron, Otsuka, and Viatrix, and co-directs a company that designs digital resources to support treatment of mental ill health. MB has received consulting fees from J&J, Engrail Therapeutics, CHDR, and travel expenses from Lundbeck. He was previously employed by P1vital Ltd. All other authors report no competing interests.

Supplementary material

Supplementary material is available at *Brain* online.

Author Contributions

JPR conceptualized the review and led the writing of the original draft. ILL, KS and THN reviewed the literature and wrote a first draft of the manuscript. All authors contributed to the development of the manuscript and have read and approved the final version of the manuscript.

References

1. Widlöcher DJ. Psychomotor retardation: Clinical, theoretical, and psychometric aspects. *Psychiatric Clinics of North America*. 1983;6(1):27-40.
2. World Health Organization (WHO). *International Classification of Diseases, Eleventh Revision (ICD-11)*.; 2019.
3. Walther S, Alexaki D, Weiss F, et al. Psychomotor Slowing in Psychosis and Inhibitory Repetitive Transcranial Magnetic Stimulation. *JAMA Psychiatry*. 2024;81(6):563-571. doi:10.1001/jamapsychiatry.2024.0026
4. Osborne KJ, Walther S, Shankman SA, Mittal VA. Psychomotor slowing in Schizophrenia: Implications for endophenotype and biomarker development. *Biomarkers in Neuropsychiatry*. 2020;2:100016. doi:10.1016/j.bionps.2020.100016
5. Morrens M, Hulstijn W, Sabbe B. Psychomotor Slowing in Schizophrenia. *Schizophrenia Bulletin*. 2007;33(4):1038-1053. doi:10.1093/schbul/sbl051
6. Bennabi D, Vandel P, Papaxanthis C, Pozzo T, Haffen E. Psychomotor Retardation in Depression: A Systematic Review of Diagnostic, Pathophysiologic, and Therapeutic Implications. *BioMed Research International*. 2013;2013(1):158746. doi:10.1155/2013/158746

- 1 7. Buyukdura JS, McClintock SM, Croarkin PE. Psychomotor retardation in depression:
2 Biological underpinnings, measurement, and treatment. *Progress in Neuro-*
3 *Psychopharmacology and Biological Psychiatry*. 2011;35(2):395-409.
4 doi:10.1016/j.pnpbp.2010.10.019
- 5 8. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What Did
6 STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With
7 Depression. *PS*. 2009;60(11):1439-1445. doi:10.1176/ps.2009.60.11.1439
- 8 9. Haber SN, Knutson B. The Reward Circuit: Linking Primate Anatomy and Human
9 Imaging. *Neuropsychopharmacol*. 2010;35(1):4-26. doi:10.1038/npp.2009.129
- 10 10. Jarbo K, Verstynen TD. Converging Structural and Functional Connectivity of
11 Orbitofrontal, Dorsolateral Prefrontal, and Posterior Parietal Cortex in the Human Striatum.
12 *J Neurosci*. 2015;35(9):3865-3878. doi:10.1523/JNEUROSCI.2636-14.2015
- 13 11. Haber SN. Corticostriatal circuitry. *Dialogues in Clinical Neuroscience*. 2016;18(1):7-21.
14 doi:10.31887/DCNS.2016.18.1/shaber
- 15 12. Nakano K, Kayahara T, Tsutsumi T, Ushiro H. Neural circuits and functional organization
16 of the striatum. *J Neurol*. 2000;247(5):V1-V15. doi:10.1007/PL00007778
- 17 13. Galvez-Jimenez N. *Scientific Basis for the Treatment of Parkinson's Disease*. CRC Press;
18 2013.
- 19 14. Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of
20 basal ganglia; a critical reappraisal. *Nat Neurosci*. 2014;17(8):1022-1030.
21 doi:10.1038/nn.3743
- 22 15. Graybiel AM. The basal ganglia. *Current Biology*. 2000;10(14):R509-R511.
23 doi:10.1016/S0960-9822(00)00593-5
- 24 16. Takakusaki K. Functional Neuroanatomy for Posture and Gait Control. *JMD*. 2017;10(1):1-
25 17. doi:10.14802/jmd.16062
- 26 17. Oswal A, Cao C, Yeh CH, et al. Neural signatures of hyperdirect pathway activity in
27 Parkinson's disease. *Nat Commun*. 2021;12(1):5185. doi:10.1038/s41467-021-25366-0

- 1 18. Lees AJ, Hardy J, Revesz T. Parkinson's disease. *Lancet*. 2009;373(9680):2055-2066.
2 doi:10.1016/S0140-6736(09)60492-X
- 3 19. Gazdag G, Sienaert P. Diagnosing and Treating Catatonia: An Update. *Current Psychiatry*
4 *Reviews*. 2013;9:130-135. doi:10.2174/1573400511309020007
- 5 20. Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome. *Annals of Pharmacotherapy*.
6 2016;50(11):973-981. doi:10.1177/1060028016657553
- 7 21. Feldman M, Marmol S, Margolesky J. Updated Perspectives on the Management of Drug-
8 Induced Parkinsonism (DIP): Insights from the Clinic. *Ther Clin Risk Manag*.
9 2022;18:1129-1142. doi:10.2147/TCRM.S360268
- 10 22. Rampello L, Nicoletti G, Raffaele R. Dopaminergic hypothesis for retarded depression: a
11 symptom profile for predicting therapeutical responses. *Acta Psychiatrica Scandinavica*.
12 1991;84(6):552-554. doi:10.1111/j.1600-0447.1991.tb03193.x
- 13 23. ROGERS D, LEES AJ, SMITH E, TRIMBLE M, STERN GM. BRADYPHRENIA IN
14 PARKINSON'S DISEASE AND PSYCHOMOTOR RETARDATION IN DEPRESSIVE
15 ILLNESS: AN EXPERIMENTAL STUDY. *Brain*. 1987;110(3):761-776.
16 doi:10.1093/brain/110.3.761
- 17 24. Hinkle JT, Pontone GM. Reconceptualizing Catatonia as "Psychiatric Parkinsonism." *The*
18 *American Journal of Geriatric Psychiatry*. 2023;31(12):1206-1208.
19 doi:10.1016/j.jagp.2023.07.010
- 20 25. DeLong MR. Primate models of movement disorders of basal ganglia origin. *Trends in*
21 *Neurosciences*. 1990;13(7):281-285. doi:10.1016/0166-2236(90)90110-V
- 22 26. Grafton ST. Contributions of functional imaging to understanding parkinsonian symptoms.
23 *Current Opinion in Neurobiology*. 2004;14(6):715-719. doi:10.1016/j.conb.2004.10.010
- 24 27. Flint AJ, Black SE, Campbell-Taylor I, Gailey GF, Levinton C. Abnormal speech
25 articulation, psychomotor retardation, and subcortical dysfunction in major depression.
26 *Journal of Psychiatric Research*. 1993;27(3):309-319. doi:10.1016/0022-3956(93)90041-Y

- 1 28. Gurd JM, Bessell N, Watson I, Coleman J. Motor speech versus digit control in Parkinson's
2 disease: A cognitive neuropsychology investigation. *Clinical Linguistics & Phonetics*.
3 1998;12(5):357-378. doi:10.1080/02699209808985231
- 4 29. Canter GJ. Speech Characteristics of Patients with Parkinson's Disease: I. Intensity, Pitch,
5 and Duration. *Journal of Speech and Hearing Disorders*. 1963;28(3):221-229.
6 doi:10.1044/jshd.2803.221
- 7 30. Nonnekes J, Giladi N, Guha A, Fietzek UM, Bloem BR, Růžicka E. Gait festination in
8 parkinsonism: introduction of two phenotypes. *J Neurol*. 2019;266(2):426-430.
9 doi:10.1007/s00415-018-9146-7
- 10 31. Deuschländer AB, Ross OA, Dickson DW, Wszolek ZK. Atypical parkinsonian
11 syndromes: a general neurologist's perspective. *European Journal of Neurology*.
12 2018;25(1):41-58. doi:10.1111/ene.13412
- 13 32. Ling H, Massey LA, Lees AJ, Brown P, Day BL. Hypokinesia without decrement
14 distinguishes progressive supranuclear palsy from Parkinson's disease. *Brain*. 2012;135(Pt
15 4):1141-1153. doi:10.1093/brain/aws038
- 16 33. Shin HW, Chung SJ. Drug-induced parkinsonism. *Journal of clinical neurology (Seoul,
17 Korea)*. 2012;8(1):15-21. doi:10.3988/jcn.2012.8.1.15
- 18 34. Factor, Stewart A. Neuroleptic malignant syndrome. In: *Drug Induced Movement
19 Disorders*. 2nd ed. Blackwell Publishing; 2005. Accessed December 9, 2024.
20 [https://www.wiley.com/en-fr/Drug+Induced+Movement+Disorders%2C+2nd+Edition-p-](https://www.wiley.com/en-fr/Drug+Induced+Movement+Disorders%2C+2nd+Edition-p-9781405137553)
21 [9781405137553](https://www.wiley.com/en-fr/Drug+Induced+Movement+Disorders%2C+2nd+Edition-p-9781405137553)
- 22 35. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis
23 of 115 cases. *Biological Psychiatry*. 1987;22(8):1004-1020. doi:10.1016/0006-
24 3223(87)90010-2
- 25 36. Paparella G, Fasano A, Hallett M, Berardelli A, Bologna M. Emerging concepts on
26 bradykinesia in non-parkinsonian conditions. *European Journal of Neurology*.
27 2021;28(7):2403-2422. doi:10.1111/ene.14851

37. Tang TS, Chen X, Liu J, Bezprozvanny I. Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease. *J Neurosci.* 2007;27(30):7899-7910. doi:10.1523/JNEUROSCI.1396-07.2007
38. Wüthrich F, Nabb CB, Mittal VA, Shankman SA, Walther S. Actigraphically measured psychomotor slowing in depression: systematic review and meta-analysis. *Psychol Med.* 2022;52(7):1208-1221. doi:10.1017/S0033291722000903
39. Sobin C, Sackeim HA. Psychomotor symptoms of depression. *Am J Psychiatry.* 1997;154(1):4-17. doi:10.1176/ajp.154.1.4
40. Dantchev N, Widlöcher DJ. The measurement of retardation in depression. *J Clin Psychiatry.* 1998;59 Suppl 14:19-25.
41. Caligiuri MP, Ellwanger J. Motor and cognitive aspects of motor retardation in depression. *Journal of Affective Disorders.* 2000;57(1):83-93. doi:10.1016/S0165-0327(99)00068-3
42. Rogers MA, Bradshaw JL, Pantelis C, Phillips JG. Frontostriatal deficits in unipolar major depression. *Brain Research Bulletin.* 1998;47(4):297-310. doi:10.1016/S0361-9230(98)00126-9
43. Sachdev P, Aniss AM. Slowness of movement in melancholic depression. *Biological Psychiatry.* 1994;35(4):253-262. doi:10.1016/0006-3223(94)91256-4
44. Dawkins E, Cruden-Smith L, Carter B, et al. Catatonia Psychopathology and Phenomenology in a Large Dataset. *Frontiers in Psychiatry.* 2022;0:977. doi:10.3389/FPSYT.2022.886662
45. Shorter E, Fink M. *The Madness of Fear : A History of Catatonia.* Oxford University Press; 2018.
46. Mortimer JA, Pirozzolo FJ, Hansch EC, Webster DD. Relationship of motor symptoms to intellectual deficits in Parkinson disease. *Neurology.* 1982;32(2):133-133. doi:10.1212/WNL.32.2.133
47. Reichmann H, Brecht MH, Köster J, Kraus PH, Lemke MR. Pramipexole in Routine Clinical Practice. *CNS Drugs.* 2003;17(13):965-973. doi:10.2165/00023210-200317130-00003

- 1 48. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, Depression, and
2 Motor Functioning in Parkinson's Disease During Treatment With Pramipexole. *JNP*.
3 2005;17(2):214-220. doi:10.1176/jnp.17.2.214
- 4 49. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related
5 deficits. *Trends in Neurosciences*. 2012;35(1):68-77. doi:10.1016/j.tins.2011.11.005
- 6 50. Cubo E, Benito-León J, Coronell C, Armesto D, on behalf of the ANIMO Study Group.
7 Clinical Correlates of Apathy in Patients Recently Diagnosed with Parkinson's Disease:
8 The ANIMO Study. *Neuroepidemiology*. 2012;38(1):48-55. doi:10.1159/000334314
- 9 51. Oguru M, Tachibana H, Toda K, Okuda B, Oka N. Apathy and Depression in Parkinson
10 Disease. *J Geriatr Psychiatry Neurol*. 2010;23(1):35-41. doi:10.1177/0891988709351834
- 11 52. Skorvanek M, Rosenberger J, Gdovinova Z, et al. Apathy in Elderly Nondemented Patients
12 With Parkinson's Disease: Clinical Determinants and Relationship to Quality of Life. *J*
13 *Geriatr Psychiatry Neurol*. 2013;26(4):237-243. doi:10.1177/0891988713500587
- 14 53. Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease:
15 clinical features, neural substrates, diagnosis, and treatment. *The Lancet Neurology*.
16 2015;14(5):518-531. doi:10.1016/S1474-4422(15)00019-8
- 17 54. Levy R, Dubois B. Apathy and the Functional Anatomy of the Prefrontal Cortex–Basal
18 Ganglia Circuits. *Cerebral Cortex*. 2006;16(7):916-928. doi:10.1093/cercor/bhj043
- 19 55. Wang S, Leri F, Rizvi SJ. Anhedonia as a central factor in depression: Neural mechanisms
20 revealed from preclinical to clinical evidence. *Progress in Neuro-Psychopharmacology and*
21 *Biological Psychiatry*. 2021;110:110289. doi:10.1016/j.pnpbp.2021.110289
- 22 56. Butterfield LC, Cimino CR, Oelke LE, Hauser RA, Sanchez-Ramos J. The independent
23 influence of apathy and depression on cognitive functioning in Parkinson's disease.
24 *Neuropsychology*. 2010;24(6):721-730. doi:10.1037/a0019650
- 25 57. Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive
26 dysfunctions in Parkinson's disease without dementia. *J Neurol*. 2009;256(4):632-638.
27 doi:10.1007/s00415-009-0146-5

58. Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. *Nat Rev Neurosci*. 2018;19(8):470-484. doi:10.1038/s41583-018-0029-9
59. Costello H, Husain M, Roiser JP. Apathy and Motivation: Biological Basis and Drug Treatment. *Annual Review of Pharmacology and Toxicology*. 2024;64(Volume 64, 2024):313-338. doi:10.1146/annurev-pharmtox-022423-014645
60. Ganos C, Kassavetis P, Cerdan M, et al. Revisiting the Syndrome of “Obsessional Slowness.” *Movement Disorders Clinical Practice*. 2015;2(2):163-169. doi:10.1002/mdc3.12140
61. Lemke MR, Puhl P, Koethe N, Winkler T. Psychomotor retardation and anhedonia in depression. *Acta Psychiatrica Scandinavica*. 1999;99(4):252-256. doi:10.1111/j.1600-0447.1999.tb07221.x
62. Bareeqa SB, Samar SS, Kamal S, et al. Prodromal Depression and Subsequent Risk of Developing Parkinson’s Disease: A Systematic Review With meta-analysis. *Neurodegenerative Disease Management*. 2022;12(3):155-164. doi:10.2217/nmt-2022-0001
63. Wang S, Mao S, Xiang D, Fang C. Association between depression and the subsequent risk of Parkinson’s disease: A meta-analysis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2018;86:186-192. doi:10.1016/j.pnpbp.2018.05.025
64. Du Y, Tang D, Yang G, Xu D. Depression and the risk of Parkinson’s disease: A Mendelian randomization study. *Medicine*. 2025;104(8):e41658. doi:10.1097/MD.00000000000041658
65. Adams MJ, Streit F, Meng X, et al. Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. *Cell*. 2025;188(3):640-652.e9. doi:10.1016/j.cell.2024.12.002
66. Kendler KS, Aggen SH, Neale MC. Evidence for Multiple Genetic Factors Underlying DSM-IV Criteria for Major Depression. *JAMA Psychiatry*. 2013;70(6):599-607. doi:10.1001/jamapsychiatry.2013.751

67. Jaimes-Albornoz W, Ruiz de Pellon-Santamaria A, Nizama-Vía A, Isetta M, Albajar I, Serra-Mestres J. Catatonia in older adults: A systematic review. *World J Psychiatry*. 2022;12(2):348-367. doi:10.5498/wjp.v12.i2.348
68. Trzepacz PT, Murcko AC, Gillespie MP. Progressive Supranuclear Palsy Misdiagnosed as Schizophrenia. *The Journal of Nervous and Mental Disease*. 1985;173(6):377.
69. Poyraz BÇ, Aksoy Poyraz C, Yassa A, Arikan MK, Gündüz A, Kiziltan G. Recurrent Catatonia in Parkinson Disease. *Journal of Clinical Psychopharmacology*. 2016;36(1):104. doi:10.1097/JCP.0000000000000443
70. Ramesh V, Sharma A, Sharma V, Somani A. Treatment of Catatonia in Parkinson's Disease with Electroconvulsive Therapy. *Ann Indian Acad Neurol*. 2019;22(4):501-503. doi:10.4103/aian.AIAN_308_18
71. Hsu CW, Lin CC, Huang TL. A Case Report of Intramuscular Lorazepam in Catatonia of a Parkinson's Disease Patient after Deep Brain Stimulation. *Psychiatr Danub*. 2018;30(1):104-106. doi:10.24869/psyd.2018.104
72. Kamigaichi R, Kubo S, Ishikawa K, et al. Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report. *Eur J Neurol*. 2009;16(2):e6. doi:10.1111/j.1468-1331.2008.02357.x
73. Lakshmana R, Sundram S, Cairns F. Dementia with Lewy Bodies (DLB) presenting with catatonic symptoms. *Psychogeriatrics*. 2006;6(1):31-34. doi:10.1111/j.1479-8301.2006.00108.x
74. Xiong GL, Palomino A, Kahn DR, Bourgeois JA. Antipsychotic Induced Catatonia: A Case of Probable Dementia With Lewy Bodies. *JNP*. 2009;21(4):472-473. doi:10.1176/jnp.2009.21.4.472
75. Saito Y, Noto K, Kobayashi R, et al. Catatonia as the Initial Manifestation of Dementia with Lewy Bodies. *Am J Case Rep*. 2021;22:e932018-1-e932018-4. doi:10.12659/AJCR.932018
76. Suzuki K, Awata S, Nakagawa K, Takano T, Matsuoka H. Catatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy. *Movement Disorders*. 2006;21(1):123-124. doi:10.1002/mds.20749

- 1 77. Kamigaichi R, Kubo S, Ishikawa K, et al. Effective control of catatonia in Parkinson's
2 disease by electroconvulsive therapy: a case report. *Euro J of Neurology*. 2009;16(2).
3 doi:10.1111/j.1468-1331.2008.02357.x
- 4 78. Pollini L, Galosi S, Nardecchia F, et al. Parkinsonism, Intellectual Disability, and Catatonia
5 in a Young Male With MECP2 Variant. *Movement Disorders Clinical Practice*.
6 2020;7(1):118-119. doi:10.1002/mdc3.12865
- 7 79. Galosi S, Martinelli S, Pannone L, et al. Co-occurring SYNJ1 and SHANK3 variants in a
8 girl with intellectual disability, early-onset parkinsonism and catatonic episodes.
9 *Parkinsonism & Related Disorders*. 2021;84:5-7.
10 doi:10.1016/J.PARKRELDIS.2020.12.022
- 11 80. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two. *Biol Psychiatry*.
12 1996;39(1):1-4. doi:10.1016/0006-3223(95)00552-8
- 13 81. Lang FU, Lang S, Becker T, Jäger M. Neuroleptic malignant syndrome or catatonia?
14 Trying to solve the catatonic dilemma. *Psychopharmacology*. 2015;232(1):1-5.
15 doi:10.1007/s00213-014-3807-8
- 16 82. Berardi D, Amore M, Keck PE, Troia M, Dell'Atti M. Clinical and pharmacologic risk
17 factors for neuroleptic malignant syndrome: A case-control study. *Biological Psychiatry*.
18 1998;44(8):748-754. doi:10.1016/S0006-3223(97)00530-1
- 19 83. Koch M, Chandragiri S, Rizvi S, Petrides G, Francis A. Catatonic signs in neuroleptic
20 malignant syndrome. *Comprehensive Psychiatry*. 2000;41(1):73-75. doi:10.1016/S0010-
21 440X(00)90135-4
- 22 84. Caroff SN, Mann SC, Keck PEJ, Francis A. Residual Catatonic State Following
23 Neuroleptic Malignant Syndrome. *Journal of Clinical Psychopharmacology*.
24 2000;20(2):257.
- 25 85. Ihara M, Kohara N, Urano F, et al. Neuroleptic malignant syndrome with prolonged
26 catatonia in a dopa-responsive dystonia patient. *Neurology*. 2002;59(7):1102-1104.
27 doi:10.1212/WNL.59.7.1102

86. Carroll BT, Spetie L. Catatonia on the Consultation-Liaison Service: A Replication Study: <http://dx.doi.org/10.2190/GTPP-MHH3-HKCP-R2NH>. 2004;24(4):329-337.
doi:10.2190/GTPP-MHH3-HKCP-R2NH
87. Funayama M, Takata T, Koreki A, Ogino S, Mimura M. Catatonic Stupor in Schizophrenic Disorders and Subsequent Medical Complications and Mortality. *Psychosomatic Medicine*. 2018;80(4):370. doi:10.1097/PSY.0000000000000574
88. Lee JWY. Neuroleptic-Induced Catatonia: Clinical Presentation, Response to Benzodiazepines, and Relationship to Neuroleptic Malignant Syndrome. *Journal of Clinical Psychopharmacology*. 2010;30(1):3. doi:10.1097/JCP.0b013e3181c9bfe6
89. Amin F, Davidson M, Davis KL. Homovanillic Acid Measurement in Clinical Research: A Review of Methodology. *Schizophrenia Bulletin*. 1992;18(1):123-148.
doi:10.1093/schbul/18.1.123
90. Johansson B, Roos BE. 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. *Life Sciences*. 1967;6(13):1449-1454. doi:10.1016/0024-3205(67)90193-2
91. Herbert MK, Kuiperij HB, Bloem BR, Verbeek MM. Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. *J Neurol*. 2013;260(12):3129-3133. doi:10.1007/s00415-013-7126-5
92. Papeschi R, Molina-Negro P, Sourkes TL, Hardy J, Bertrand C. Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other dyskinesias. *Neurology*. 1970;20(10):991-991. doi:10.1212/WNL.20.10.991
93. Nishijima K, Ishiguro T. [Clinical course and CSF monoamine metabolism in neuroleptic malignant syndrome--a study of nine typical cases and five mild cases]. *Seishin Shinkeigaku Zasshi*. 1989;91(6):429-456.
94. Kasa K, Otsuki S, Yamamoto M, Sato M, Kuroda H, Ogawa N. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. *Biol Psychiatry*. 1982;17(8):877-883.
95. Mitani H, Shirayama Y, Yamada T, Kawahara R. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients.

- 1 *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2006;30(3):531-534.
2 doi:10.1016/j.pnpbp.2005.11.021
- 3 96. Sher L, Oquendo MA, Li S, et al. Lower CSF Homovanillic Acid Levels in Depressed
4 Patients with a History of Alcoholism. *Neuropsychopharmacol*. 2003;28(9):1712-1719.
5 doi:10.1038/sj.npp.1300231
- 6 97. Sher L, Mann JJ, Traskman-Bendz L, et al. Lower cerebrospinal fluid homovanillic acid
7 levels in depressed suicide attempters. *Journal of Affective Disorders*. 2006;90(1):83-89.
8 doi:10.1016/j.jad.2005.10.002
- 9 98. Roy A, Pickar D, Linnoila M, Doran AR, Ninan P, Paul SM. Cerebrospinal fluid
10 monoamine and monoamine metabolite concentrations in melancholia. *Psychiatry*
11 *Research*. 1985;15(4):281-292. doi:10.1016/0165-1781(85)90065-4
- 12 99. Yoshimura R, Okamoto N, Ikenouchi A. Comparison of plasma catecholamine metabolites
13 in melancholic and non-melancholic depression. *Psychiatry Research Communications*.
14 2022;2(3):100063. doi:10.1016/j.psycom.2022.100063
- 15 100. van Praag HM, Korf J. Retarded depression and the dopamine metabolism.
16 *Psychopharmacologia*. 1971;19(2):199-203. doi:10.1007/BF00402643
- 17 101. Leckman JF, Charney DS, Nelson CR, Heninger GR, Bowers MB. CSF TRYPTOPHAN,
18 5-HIAA AND HVA IN 132 PSYCHIATRIC PATIENTS CATEGORIZED BY
19 DIAGNOSIS AND CLINICAL STATE. In: Angrist B, Burrows GD, Lader M, Lingjaerde
20 O, Sedvall G, Wheatley D, eds. *Recent Advances in Neuropsychopharmacology*.
21 Pergamon; 1981:289-297. doi:10.1016/B978-0-08-026382-3.50042-6
- 22 102. Post RM, Kotin J, Goodwin FK, Gordon EK. Psychomotor Activity and Cerebrospinal
23 Fluid Amine Metabolites in Affective Illness. *AJP*. 1973;130(1):67-72.
24 doi:10.1176/ajp.130.1.67
- 25 103. Northoff G, Demisch L, Wenke J, Pflug B. Plasma homovanillic acid concentrations in
26 catatonia. *Biological Psychiatry*. 1996;39(6):436-443. doi:10.1016/0006-3223(95)00184-0
- 27 104. Northoff G, Wenke J, Demisch L, Eckert J, Gille B, Pflug B. Catatonia: short-term response
28 to lorazepam and dopaminergic metabolism. *Psychopharmacology*. 1995;122(2):182-186.
29 doi:10.1007/BF02246093

105. Chaudhury D, Walsh JJ, Friedman AK, et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. *Nature*. 2013;493(7433):532-536. doi:10.1038/nature11713
106. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Cerebral Metabolism of 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine in the Primate. *Journal of Neurochemistry*. 1987;48(4):1077-1082. doi:10.1111/j.1471-4159.1987.tb05629.x
107. Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. *Nat Rev Neurosci*. 2010;11(11):760-772. doi:10.1038/nrn2915
108. Aquilonius SM, Bertröm K, Eckernäs SÅ, et al. In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. *Acta Neurologica Scandinavica*. 1987;76(4):283-287. doi:10.1111/j.1600-0404.1987.tb03582.x
109. BROOKS DJ, SALMON EP, MATHIAS CJ, et al. THE RELATIONSHIP BETWEEN LOCOMOTOR DISABILITY, AUTONOMIC DYSFUNCTION, AND THE INTEGRITY OF THE STRIATAL DOPAMINERGIC SYSTEM IN PATIENTS WITH MULTIPLE SYSTEM ATROPHY, PURE AUTONOMIC FAILURE, AND PARKINSON'S DISEASE, STUDIED WITH PET. *Brain*. 1990;113(5):1539-1552. doi:10.1093/brain/113.5.1539
110. Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. *J Neurol Sci*. 1999;166(2):141-151. doi:10.1016/s0022-510x(99)00127-6
111. Leenders KL, Salmon EP, Tyrrell P, et al. The Nigrostriatal Dopaminergic System Assessed In Vivo by Positron Emission Tomography in Healthy Volunteer Subjects and Patients With Parkinson's Disease. *Archives of Neurology*. 1990;47(12):1290-1298. doi:10.1001/archneur.1990.00530120034007
112. Vingerhoets FJG, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? *Annals of Neurology*. 1997;41(1):58-64. doi:10.1002/ana.410410111

- 1 113. Lee MJ, Kim SL, Lyoo CH, Rinne JO, Lee MS. Impact of regional striatal dopaminergic
2 function on kinematic parameters of Parkinson's disease. *J Neural Transm.*
3 2015;122(5):669-677. doi:10.1007/s00702-014-1296-x
- 4 114. Kaasinen V, Vahlberg T, Stoessl AJ, Strafella AP, Antonini A. Dopamine Receptors in
5 Parkinson's Disease: A Meta-Analysis of Imaging Studies. *Movement Disorders.*
6 2021;36(8):1781-1791. doi:10.1002/mds.28632
- 7 115. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT
8 functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
9 *NeuroImage.* 2004;23(1):1-16. doi:10.1016/j.neuroimage.2004.04.039
- 10 116. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RSJ. Asymmetrical pre-synaptic
11 and post-synaptic changes in the striatal dopamine projection in dopa naïve parkinsonism:
12 Diagnostic implications of the D2 receptor status. *Brain.* 1993;116(4):853-867.
13 doi:10.1093/brain/116.4.853
- 14 117. Rinne JO, Portin R, Ruottinen H, et al. Cognitive Impairment and the Brain Dopaminergic
15 System in Parkinson Disease: [18F]Fluorodopa Positron Emission Tomographic Study.
16 *Archives of Neurology.* 2000;57(4):470-475. doi:10.1001/archneur.57.4.470
- 17 118. Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain
18 metabolic changes with cognitive dysfunction in early Parkinson's disease. *Neurobiology of*
19 *Aging.* 2012;33(1):206.e29-206.e39. doi:10.1016/j.neurobiolaging.2010.09.004
- 20 119. Rinne JO, Portin R, Ruottinen H, et al. Cognitive Impairment and the Brain Dopaminergic
21 System in Parkinson Disease: [18F]Fluorodopa Positron Emission Tomographic Study.
22 *Archives of Neurology.* 2000;57(4):470-475. doi:10.1001/archneur.57.4.470
- 23 120. Vriend C, van Balkom TD, van Druningen C, et al. Processing speed is related to striatal
24 dopamine transporter availability in Parkinson's disease. *NeuroImage: Clinical.*
25 2020;26:102257. doi:10.1016/j.nicl.2020.102257
- 26 121. Mattila PM, Röyttä M, Lönnberg P, Marjamäki P, Helenius H, Rinne JO. Choline
27 acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation
28 to cognitive impairment. *Acta Neuropathol.* 2001;102(2):160-166.
29 doi:10.1007/s004010100372

122. Costello H, Yamamori Y, Reeves S, Schrag AE, Howard R, Roiser JP. Longitudinal decline in striatal dopamine transporter binding in Parkinson's disease: associations with apathy and anhedonia. *J Neurol Neurosurg Psychiatry*. 2023;94(10):863-870. doi:10.1136/jnnp-2022-330790
123. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. *Brain*. 2005;128(6):1314-1322. doi:10.1093/brain/awh445
124. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it? *Movement Disorders*. 2003;18(S7):S43-S51. doi:10.1002/mds.10579
125. Rossi C, Frosini D, Volterrani D, et al. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. *European Journal of Neurology*. 2010;17(4):626-630. doi:10.1111/j.1468-1331.2009.02898.x
126. Schiess MC, Zheng H, Soukup VM, Bonnen JG, Nauta HJW. Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. *Parkinsonism & Related Disorders*. 2000;6(2):69-76. doi:10.1016/S1353-8020(99)00051-6
127. Neumeyer JL, Campbell A, Wang S, et al. N-.omega.-Fluoroalkyl Analogs of (1R)-2.beta.-Carbomethoxy-3.beta.-(4-iodophenyl)tropane (.beta.-CIT): Radiotracers for Positron Emission Tomography and Single Photon Emission Computed Tomography Imaging of Dopamine Transporters. *J Med Chem*. 1994;37(11):1558-1561. doi:10.1021/jm00037a004
128. Tinazzi M, Ottaviani S, Isaias IU, et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. *Movement Disorders*. 2008;23(13):1825-1829. doi:10.1002/mds.22098
129. Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. *J Neurol*. 2009;256(6):910-915. doi:10.1007/s00415-009-5039-0
130. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: An ¹⁸F-dopa PET study. *Neurology*. 1993;43(3_part_1):552-552. doi:10.1212/WNL.43.3_Part_1.552
131. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. *Movement Disorders*. 2003;18(S7):S28-S33. doi:10.1002/mds.10575

132. Thobois S, Prange S, Scheiber C, Broussolle E. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. *Parkinsonism & Related Disorders*. 2019;59:93-100. doi:10.1016/j.parkreldis.2018.08.016
133. Jauss M, Krack P, Franz M, et al. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. *Movement Disorders*. 1996;11(6):726-728. doi:10.1002/mds.870110621
134. Haroche A, Rogers J, Plaze M, et al. Brain imaging in catatonia: systematic review and directions for future research. *Psychological Medicine*. 2020;50(10):1585-1597. doi:10.1017/S0033291720001853
135. Hietala J, Syvälahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naïve schizophrenic patients. *Lancet*. 1995;346(8983):1130-1131. doi:10.1016/s0140-6736(95)91801-9
136. Hietala J, Syvälahti E, Vilkmann H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naïve schizophrenia. *Schizophrenia Research*. 1999;35(1):41-50. doi:10.1016/S0920-9964(98)00113-3
137. Dao-Castellana MH, Paillère-Martinot ML, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. *Schizophrenia Research*. 1997;23(2):167-174. doi:10.1016/S0920-9964(96)00102-8
138. Remy P, Samson Y, Hantraye P, et al. Clinical correlates of 18Ffluorodopa uptake in five grafted Parkinsonian patients. *Annals of Neurology*. 1995;38(4):580-588. doi:10.1002/ana.410380406
139. Jauhar S, Veronese M, Nour MM, et al. The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. *Biol Psychiatry*. 2019;85(1):79-87. doi:10.1016/j.biopsych.2018.07.003
140. Arai K, Sakimoto H, Urata Y, et al. Aging-Related Catatonia with Reversible Dopamine Transporter Dysfunction in Females with Depressive Symptoms: A Case Series. *The*

- American Journal of Geriatric Psychiatry*. 2023;31(12):1200-1205.
doi:10.1016/j.jagp.2023.05.009
141. Martinot MLP, Bragulat V, Artiges E, et al. Decreased Presynaptic Dopamine Function in the Left Caudate of Depressed Patients With Affective Flattening and Psychomotor Retardation. *AJP*. 2001;158(2):314-316. doi:10.1176/appi.ajp.158.2.314
142. Li Z, He Y, Tang J, Zong X, Hu M, Chen X. Molecular imaging of striatal dopamine transporters in major depression—A meta-analysis. *Journal of Affective Disorders*. 2015;174:137-143. doi:10.1016/j.jad.2014.11.045
143. Mizuno Y, Ashok AH, Bhat BB, Jauhar S, Howes OD. Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies. *J Psychopharmacol*. 2023;37(11):1058-1069. doi:10.1177/02698811231200881
144. Ebert D, Loew T, Feistel H, Pirner A. Dopamine and depression — Striatal dopamine D2 receptor SPECT before and after antidepressant therapy. *Psychopharmacology*. 1996;126(1):91-94. doi:10.1007/BF02246416
145. Meyer JH, McNeely HE, Sagrati S, et al. Elevated Putamen D 2 Receptor Binding Potential in Major Depression With Motor Retardation: An [11 C]Raclopride Positron Emission Tomography Study. *AJP*. 2006;163(9):1594-1602. doi:10.1176/ajp.2006.163.9.1594
146. Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP. Clinical and psychometric correlates of dopamine D2 binding in depression. *Psychological Medicine*. 1997;27(6):1247-1256. doi:10.1017/S0033291797005382
147. Niccolini F, Su P, Politis M. Dopamine receptor mapping with PET imaging in Parkinson's disease. *J Neurol*. 2014;261(12):2251-2263. doi:10.1007/s00415-014-7302-2
148. LeWitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. *Movement Disorders*. 2015;30(1):64-72. doi:10.1002/mds.26082
149. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. *Neurology*. 1997;49(2):393-399. doi:10.1212/WNL.49.2.393

- 1 150. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A
2 randomized dose-ranging study. Parkinson Study Group. *JAMA*. 1997;278(2):125-130.
3 doi:10.1001/jama.1997.03550020057038
- 4 151. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of
5 early PD. *Neurology*. 1999;53(3):573-573. doi:10.1212/WNL.53.3.573
- 6 152. Parkinson Study Group. A Controlled Trial of Rasagiline in Early Parkinson Disease: The
7 TEMPO Study. *Archives of Neurology*. 2002;59(12):1937-1943.
8 doi:10.1001/archneur.59.12.1937
- 9 153. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-
10 controlled, delayed start study to assess rasagiline as a disease modifying therapy in
11 Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
12 *Mov Disord*. 2008;23(15):2194-2201. doi:10.1002/mds.22218
- 13 154. Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti aknetic
14 effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. *J Neural Transm*.
15 1975;36(3-4):303-326. doi:10.1007/BF01253131
- 16 155. Costello H, Schrag AE, Howard R, Roiser JP. Dissociable effects of dopaminergic
17 medications on depression symptom dimensions in Parkinson disease. *Nature Mental*
18 *Health*. 2024;2(8):916. doi:10.1038/s44220-024-00256-8
- 19 156. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive
20 symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-
21 controlled trial. *The Lancet Neurology*. 2010;9(6):573-580. doi:10.1016/S1474-
22 4422(10)70106-X
- 23 157. DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in
24 drug-induced extrapyramidal disorders. *Arch Gen Psychiatry*. 1976;33(5):599-602.
25 doi:10.1001/archpsyc.1976.01770050055008
- 26 158. Di Fabio R, De Filippis S, Cafariello C, et al. Low Doses of Rotigotine in Patients With
27 Antipsychotic-Induced Parkinsonism. *Clinical Neuropharmacology*. 2013;36(5):162.
28 doi:10.1097/WNF.0b013e3182a2ce3f

159. Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson's disease and other movement disorders. *The Lancet Neurology*. 2021;20(12):1048-1056. doi:10.1016/S1474-4422(21)00249-0
160. Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome: Focus on Treatment and Rechallenge. *Ann Pharmacother*. 2016;50(11):973-981. doi:10.1177/1060028016657553
161. Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. *Curr Neuroparmacol*. 2015;13(3):395-406. doi:10.2174/1570159X13999150424113345
162. Mueller PS, Vester JW, Fermaglich J. Neuroleptic Malignant Syndrome: Successful Treatment With Bromocriptine. *JAMA*. 1983;249(3):386-388. doi:10.1001/jama.1983.03330270050032
163. Panagariya A, Sharma B, Singh R, Agarwal V, Dev A. The neuroleptic malignant syndrome: A report of 14 cases from North India. *Neurology India*. 2007;55(2):166. doi:10.4103/0028-3886.32793
164. Otani K, Mihara K, Kondo T, Okada M, Kaneko S, Fukushima Y. Treatment of neuroleptic malignant syndrome with levodopa. *Human Psychopharmacology: Clinical and Experimental*. 1992;7(3):217-221. doi:10.1002/hup.470070310
165. Sechi G, Tanda F, Mutani R. Fatal hyperpyrexia after withdrawal of levodopa. *Neurology*. 1984;34(2):249-249. doi:10.1212/WNL.34.2.249
166. Sechi G, Manca S, Deiana GA, Corda DG, Pisu A, Rosati G. Acute hyponatremia and neuroleptic malignant syndrome in Parkinson's disease. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 1996;20(3):533-542. doi:10.1016/0278-5846(96)00015-2
167. Gordon P h., Frucht S j. Neuroleptic malignant syndrome in advanced Parkinson's disease. *Movement Disorders*. 2001;16(5):960-962. doi:10.1002/mds.1166
168. Serrano-Dueñas M. Neuroleptic malignant syndrome-like, or—dopaminergic malignant syndrome—due to levodopa therapy withdrawal. Clinical features in 11 patients. *Parkinsonism & Related Disorders*. 2003;9(3):175-178. doi:10.1016/S1353-8020(02)00035-4

169. Brantley EJ, Cohn JV, Babu KM. Case files of the Program in Medical Toxicology at Brown University: Amantadine withdrawal and the neuroleptic malignant syndrome. *J Med Toxicol.* 2009;5(2):92-98. doi:10.1007/BF03161096
170. Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. *J Psychopharmacol.* 2023;37(4):327-369. doi:10.1177/02698811231158232
171. Gelenberg AJ, Mandel MR. Catatonic reactions to high-potency neuroleptic drugs. *Archives of general psychiatry.* 1977;34(8):947-950.
172. Saini A, Begum N, Matti J, et al. Clozapine as a treatment for catatonia: A systematic review. *Schizophrenia Research.* 2024;263:275-281. doi:10.1016/j.schres.2022.09.021
173. Jann MW. Clozapine. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.* 1991;11(3):179-195. doi:10.1002/j.1875-9114.1991.tb02628.x
174. Lander M, Bastiampillai T, Sareen J. Review of withdrawal catatonia: what does this reveal about clozapine? *Translational Psychiatry.* 2018;8(1):139. doi:10.1038/s41398-018-0192-9
175. Bédard P, Larochelle L, Poirier LJ, Sourkes TL. Reversible effect of L-DOPA on tremor and catatonia induced by α -methyl-p-tyrosine. *Can J Physiol Pharmacol.* 1970;48(1):82-84. doi:10.1139/y70-013
176. Neppe VM. Management of Catatonic Stupor with L-Dopa. *Clinical Neuropharmacology.* 1988;11(1):90.
177. Singh A, Kulkarni SK. Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice. *Methods Find Exp Clin Pharmacol.* 2002;24(1):23-29. doi:10.1358/mf.2002.24.1.677124
178. Zeshan M, Majeed MH, Hanif A. Successful Treatment of Catatonia with Methylphenidate in a 25-Year-Old Patient With Schizophrenia. *Prim Care Companion CNS Disord.* 2018;20(2):27487. doi:10.4088/PCC.17l02163

179. Prowler ML, Weiss D, Caroff SN. Treatment of Catatonia With Methylphenidate in an Elderly Patient With Depression. *Psychosomatics*. 2010;51(1):74-76. doi:10.1016/S0033-3182(10)70662-9
180. Neuhut R, Levy R, Kondracke A. Resolution of Catatonia after Treatment with Stimulant Medication in a Patient with Bipolar Disorder. *Psychosomatics*. 2012;53(5):482-484. doi:10.1016/j.psych.2011.12.006
181. Beach SR, Gomez-Bernal F, Huffman JC, Fricchione GL. Alternative treatment strategies for catatonia: A systematic review. *General Hospital Psychiatry*. 2017;48:1-19. doi:10.1016/j.genhosppsych.2017.06.011
182. Tundo A, de Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. *Acta Psychiatrica Scandinavica*. 2019;140(2):116-125. doi:10.1111/acps.13055
183. Browning M, Cowen PJ, Galal U, et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. *The Lancet Psychiatry*. 2025;0(0). doi:10.1016/S2215-0366(25)00194-4
184. Ceci A, Garattini S, Gobbi M, Mennini T. Effect of long term amineptine treatment on pre- and postsynaptic mechanisms in rat brain. *Br J Pharmacol*. 1986;88(1):269-275.
185. Butcher LL, Engel J. Behavioral and biochemical effects of L-DOPA after peripheral decarboxylase inhibition. *Brain Research*. 1969;15(1):233-242. doi:10.1016/0006-8993(69)90322-9
186. Goodwin F, Keith H, Brodie H, Murphy D, Bunney W. ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS. *The Lancet*. 1970;295(7653):908-911. doi:10.1016/S0140-6736(70)91044-5
187. Goodwin FK, Sack RL. Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. *Advances in biochemical psychopharmacology*. 1974;12(0):261-279.
188. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. *Therapeutic Advances in Psychopharmacology*. 2016;6(2):99-144. doi:10.1177/2045125316629071

189. Herrera-Guzmán I, Gudayol-Ferré E, Lira-Mandujano J, et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. *Psychiatry Research*. 2008;160(1):72-82. doi:10.1016/j.psychres.2007.04.012
190. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. *Expert Review of Neurotherapeutics*. 2006;6(9):1249-1265. doi:10.1586/14737175.6.9.1249
191. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2007;68(6):843-853. doi:10.4088/jcp.v68n0604
192. Suchting R, Tirumalaraju V, Gareeb R, et al. Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis. *Journal of Affective Disorders*. 2021;282:1153-1160. doi:10.1016/j.jad.2021.01.021
193. Espinoza RT, Kellner CH. Electroconvulsive Therapy. *The New England Journal of Medicine*. 2022;386(7):667-672. doi:10.1056/NEJMra2034954
194. Belge JB, Van Diermen L, Schrijvers D, et al. The basal ganglia: A central hub for the psychomotor effects of electroconvulsive therapy. *Journal of Affective Disorders*. 2020;265:239-246. doi:10.1016/j.jad.2020.01.033
195. Bouckaert F, Winter FLD, Emsell L, et al. Grey matter volume increase following electroconvulsive therapy in patients with late life depression: a longitudinal MRI study. *Journal of Psychiatry and Neuroscience*. 2016;41(2):105-114. doi:10.1503/jpn.140322
196. Henry ME, Schmidt ME, Matochik JA, Stoddard EP, Potter WZ. The Effects of ECT on Brain Glucose: A Pilot FDG PET Study. *The Journal of ECT*. 2001;17(1):33.
197. Masuoka T, Tateno A, Sakayori T, et al. Electroconvulsive therapy decreases striatal dopamine transporter binding in patients with depression: A positron emission tomography study with [18F]FE-PE2I. *Psychiatry Research: Neuroimaging*. 2020;301:111086. doi:10.1016/j.pscychresns.2020.111086

- 1 198. Chiodo LA, Antelman SM. Electroconvulsive Shock: Progressive Dopamine Autoreceptor
2 Subsensitvity Independent of Repeated Treatment. *Science*. 1980;210(4471):799-801.
3 doi:10.1126/science.6254148
- 4 199. Takamiya A, Seki M, Kudo S, et al. Electroconvulsive Therapy for Parkinson's Disease: A
5 Systematic Review and Meta-Analysis. *Movement Disorders*. 2021;36(1):50-58.
6 doi:10.1002/mds.28335
- 7 200. Andersen K, Balldin J, Gottfries C g., et al. A double-blind evaluation of electroconvulsive
8 therapy in Parkinson's disease with "on-off" phenomena. *Acta Neurologica Scandinavica*.
9 1987;76(3):191-199. doi:10.1111/j.1600-0404.1987.tb03566.x
- 10 201. Erchinger VJ, Ersland L, Aukland SM, Abbott CC, Oltedal L. Magnetic Resonance
11 Spectroscopy in Depressed Subjects Treated With Electroconvulsive Therapy—A
12 Systematic Review of Literature. *Front Psychiatry*. 2021;12.
13 doi:10.3389/fpsy.2021.608857
- 14 202. Mitchell ND, Baker GB. An update on the role of glutamate in the pathophysiology of
15 depression. *Acta Psychiatrica Scandinavica*. 2010;122(3):192-210. doi:10.1111/j.1600-
16 0447.2009.01529.x
- 17 203. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-
18 Hydroxytryptophan as Reserpine Antagonists. *Nature*. 1957;180(4596):1200-1200.
19 doi:10.1038/1801200a0
- 20 204. Costa KM, Schoenbaum G. Dopamine. *Current Biology*. 2022;32(15):R817-R824.
21 doi:10.1016/j.cub.2022.06.060
- 22 205. da Silva JA, Tecuapetla F, Paixão V, Costa RM. Dopamine neuron activity before action
23 initiation gates and invigorates future movements. *Nature*. 2018;554(7691):244-248.
24 doi:10.1038/nature25457
- 25 206. Jeong H, Taylor A, Floeder JR, et al. Mesolimbic dopamine release conveys causal
26 associations. *Science*. 2022;378(6626):eabq6740. doi:10.1126/science.abq6740
- 27 207. Eshel N, Bukwich M, Rao V, Hemmelder V, Tian J, Uchida N. Arithmetic and local
28 circuitry underlying dopamine prediction errors. *Nature*. 2015;525(7568):243-246.
29 doi:10.1038/nature14855

208. Alberico SL, Cassell MD, Narayanan NS. The vulnerable ventral tegmental area in Parkinson's disease. *Basal Ganglia*. 2015;5(2):51-55. doi:10.1016/j.baga.2015.06.001
209. Mogenson GJ, Jones DL, Yim CY. From motivation to action: Functional interface between the limbic system and the motor system. *Progress in Neurobiology*. 1980;14(2):69-97. doi:10.1016/0301-0082(80)90018-0
210. Salamone JD, Correa M, Mingote SM, Weber SM, Farrar AM. Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression. *Current Psychiatry Reviews*. 2006;2(2):267-280. doi:10.2174/157340006776875914
211. Mazzoni P, Hristova A, Krakauer JW. Why Don't We Move Faster? Parkinson's Disease, Movement Vigor, and Implicit Motivation. *J Neurosci*. 2007;27(27):7105-7116. doi:10.1523/JNEUROSCI.0264-07.2007
212. Chong TTJ, Bonnelle V, Manohar S, et al. Dopamine enhances willingness to exert effort for reward in Parkinson's disease. *Cortex*. 2015;69:40-46. doi:10.1016/j.cortex.2015.04.003
213. Gepshtein S, Li X, Snider J, Plank M, Lee D, Poizner H. Dopamine function and the efficiency of human movement. *J Cogn Neurosci*. 2014;26(3):645-657. doi:10.1162/jocn_a_00503
214. Salamone JD, Yohn SE, López-Cruz L, San Miguel N, Correa M. Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology. *Brain*. 2016;139(5):1325-1347. doi:10.1093/brain/aww050
215. Santangelo G, Vitale C, Picillo M, et al. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. *Parkinsonism & Related Disorders*. 2015;21(5):489-493. doi:10.1016/j.parkreldis.2015.02.015
216. Mirabella G. Should I stay or should I go? Conceptual underpinnings of goal-directed actions. *Front Syst Neurosci*. 2014;8. doi:10.3389/fnsys.2014.00206
217. Schultz W, Dayan P, Montague PR. A Neural Substrate of Prediction and Reward. *Science*. 1997;275(5306):1593-1599. doi:10.1126/science.275.5306.1593

218. Houk JC, Davis JL, Beiser DG. A Model of How the Basal Ganglia Generate and Use Neural Signals That Predict Reinforcement. In: *Models of Information Processing in the Basal Ganglia*. MIT Press; 1994:249-270. Accessed October 6, 2024. <https://ieeexplore.ieee.org/document/6287670>
219. Daniel R, Pollmann S. A universal role of the ventral striatum in reward-based learning: Evidence from human studies. *Neurobiology of Learning and Memory*. 2014;114:90-100. doi:10.1016/j.nlm.2014.05.002
220. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. *Trends in Neurosciences*. 1990;13(7):266-271. doi:10.1016/0166-2236(90)90107-L
221. Cooper JC, Dunne S, Furey T, O'Doherty JP. Human Dorsal Striatum Encodes Prediction Errors during Observational Learning of Instrumental Actions. *J Cogn Neurosci*. 2012;24(1):106-118. doi:10.1162/jocn_a_00114
222. Araújo A, Duarte IC, Sousa T, et al. Neural inhibition as implemented by an actor-critic model involves the human dorsal striatum and ventral tegmental area. *Sci Rep*. 2024;14(1):6363. doi:10.1038/s41598-024-56161-8
223. Cragg SJ, Hille CJ, Greenfield SA. Dopamine release and uptake dynamics within nonhuman primate striatum in vitro. *J Neurosci*. 2000;20(21):8209-8217. doi:10.1523/JNEUROSCI.20-21-08209.2000
224. Cools R. Chemistry of the Adaptive Mind: Lessons from Dopamine. *Neuron*. 2019;104(1):113-131. doi:10.1016/j.neuron.2019.09.035
225. Haruno M, Kawato M. Different Neural Correlates of Reward Expectation and Reward Expectation Error in the Putamen and Caudate Nucleus During Stimulus-Action-Reward Association Learning. *Journal of Neurophysiology*. 2006;95(2):948-959. doi:10.1152/jn.00382.2005
226. Delgado MR, Miller MM, Inati S, Phelps EA. An fMRI study of reward-related probability learning. *NeuroImage*. 2005;24(3):862-873. doi:10.1016/j.neuroimage.2004.10.002

227. Balleine BW, Delgado MR, Hikosaka O. The Role of the Dorsal Striatum in Reward and Decision-Making. *J Neurosci.* 2007;27(31):8161-8165. doi:10.1523/JNEUROSCI.1554-07.2007
228. Koeppe MJ, Gunn RN, Lawrence AD, et al. Evidence for striatal dopamine release during a video game. *Nature.* 1998;393(6682):266-268. doi:10.1038/30498
229. Zald DH, Boileau I, El-Dearedy W, et al. Dopamine Transmission in the Human Striatum during Monetary Reward Tasks. *J Neurosci.* 2004;24(17):4105-4112. doi:10.1523/JNEUROSCI.4643-03.2004
230. Pessiglione M, Czernecki V, Pillon B, et al. An effect of dopamine depletion on decision-making: the temporal coupling of deliberation and execution. *J Cogn Neurosci.* 2005;17(12):1886-1896. doi:10.1162/089892905775008661
231. Salamone JD. Complex motor and sensorimotor functions of striatal and accumbens dopamine: involvement in instrumental behavior processes. *Psychopharmacology.* 1992;107(2):160-174. doi:10.1007/BF02245133
232. Burleigh-Jacobs A, Horak FB, Nutt JG, Obeso JA. Step initiation in Parkinson's disease: Influence of levodopa and external sensory triggers. *Movement Disorders.* 1997;12(2):206-215. doi:10.1002/mds.870120211
233. Delval A, Tard C, Defebvre L. Why we should study gait initiation in Parkinson's disease. *Neurophysiologie Clinique/Clinical Neurophysiology.* 2014;44(1):69-76. doi:10.1016/j.neucli.2013.10.127
234. Praamstra P, Stegeman DF, Cools AR, Horstink MW. Reliance on external cues for movement initiation in Parkinson's disease. Evidence from movement-related potentials. *Brain.* 1998;121(1):167-177. doi:10.1093/brain/121.1.167
235. Glickstein M, Stein J. Paradoxical movement in Parkinson's disease. *Trends in Neurosciences.* 1991;14(11):480-482. doi:10.1016/0166-2236(91)90055-Y
236. Russo Y, Stuart S, Silva-Batista C, Brumbach B, Vannozzi G, Mancini M. Does visual cueing improve gait initiation in people with Parkinson's disease? *Human Movement Science.* 2022;84:102970. doi:10.1016/j.humov.2022.102970

237. Bonanni L, Thomas A, Onofrij M. Paradoxical kinesia in parkinsonian patients surviving earthquake. *Movement Disorders*. 2010;25(9):1302-1304. doi:10.1002/mds.23075
238. Robbins TW, Brown VJ. The Role of the Striatum in the Mental Chronometry of Action: A Theoretical Review. *Reviews in the Neurosciences*. 1990;2(4):181-214. doi:10.1515/REVNEURO.1990.2.4.181
239. Hirjak D, Rogers JP, Wolf RC, et al. Catatonia. *Nat Rev Dis Primers*. 2024;10(1):1-18. doi:10.1038/s41572-024-00534-w
240. Wijemanne S, Jankovic J. Movement disorders in catatonia. *J Neurol Neurosurg Psychiatry*. 2015;86(8):825-832. doi:10.1136/jnnp-2014-309098
241. BENECKE R, ROTHWELL JC, DICK JPR, DAY BL, MARSDEN CD. DISTURBANCE OF SEQUENTIAL MOVEMENTS IN PATIENTS WITH PARKINSON'S DISEASE. *Brain*. 1987;110(2):361-379. doi:10.1093/brain/110.2.361
242. BENECKE R, ROTHWELL JC, DICK JPR, DAY BL, MARSDEN CD. PERFORMANCE OF SIMULTANEOUS MOVEMENTS IN PATIENTS WITH PARKINSON'S DISEASE. *Brain*. 1986;109(4):739-757. doi:10.1093/brain/109.4.739
243. Matsumoto N, Hanakawa T, Maki S, Graybiel AM, Kimura M. Nigrostriatal Dopamine System in Learning to Perform Sequential Motor Tasks in a Predictive Manner. *Journal of Neurophysiology*. Published online August 1, 1999. doi:10.1152/jn.1999.82.2.978
244. Kawashima S, Ueki Y, Kato T, Ito K, Matsukawa N. Reduced striatal dopamine release during motor skill acquisition in Parkinson's disease. *PLOS ONE*. 2018;13(5):e0196661. doi:10.1371/journal.pone.0196661
245. Badgaiyan RD, Fischman AJ, Alpert NM. Striatal dopamine release in sequential learning. *NeuroImage*. 2007;38(3):549-556. doi:10.1016/j.neuroimage.2007.07.052
246. Graybiel AM. The Basal Ganglia and Chunking of Action Repertoires. *Neurobiology of Learning and Memory*. 1998;70(1):119-136. doi:10.1006/nlme.1998.3843
247. Kish SJ, Shannak K, Hornykiewicz O. Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease. *New England Journal of Medicine*. 1988;318(14):876-880. doi:10.1056/NEJM198804073181402

248. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. *Brain*. 1996;119(2):585-591. doi:10.1093/brain/119.2.585
249. Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol*. 2006;5(3):235-245. doi:10.1016/S1474-4422(06)70373-8
250. Politis M, Loane C. Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. *The Scientific World Journal*. 2011;11(1):172893. doi:10.1100/2011/172893
251. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's Disease: An *in vivo* 11C-DASB PET study. *Neurobiology of Disease*. 2010;40(1):216-221. doi:10.1016/j.nbd.2010.05.028
252. Gleason SD, Shannon HE. *Meta*-chlorophenylpiperazine induced changes in locomotor activity are mediated by 5-HT1 as well as 5-HT2C receptors in mice. *European Journal of Pharmacology*. 1998;341(2):135-138. doi:10.1016/S0014-2999(97)01474-X
253. Lucki I, Ward HR, Frazer A. Effect of 1-(*m*-chlorophenyl)piperazine and 1-(*m*-trifluoromethylphenyl)piperazine on locomotor activity. *The Journal of Pharmacology and Experimental Therapeutics*. 1989;249(1):155-164. doi:10.1016/S0022-3565(25)23232-3
254. Sabbe B, Hulstijn W, Maes M, Pier M, Scharpé S, Zitman F. Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of *meta*-chlorophenylpiperazine in normal volunteers. *Psychiatry Research*. 2001;105(3):151-163. doi:10.1016/S0165-1781(01)00326-2
255. Bohnen NI, Yarnall AJ, Weil RS, et al. Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches. *The Lancet Neurology*. 2022;21(4):381-392. doi:10.1016/S1474-4422(21)00377-X
256. van Nuland AJM, den Ouden HEM, Zach H, et al. GABAergic changes in the thalamocortical circuit in Parkinson's disease. *Human Brain Mapping*. 2020;41(4):1017-1029. doi:10.1002/hbm.24857

257. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. *Acta Psychiatrica Scandinavica*. 1996;93(2):137-143. doi:10.1111/j.1600-0447.1996.tb09815.x
258. Northoff G, Steinke R, Czervinka C, et al. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. *Journal of Neurology, Neurosurgery & Psychiatry*. 1999;67(4):445-450. doi:10.1136/jnnp.67.4.445
259. Tritsch NX, Granger AJ, Sabatini BL. Mechanisms and functions of GABA co-release. *Nat Rev Neurosci*. 2016;17(3):139-145. doi:10.1038/nrn.2015.21
260. HASLER G. PATHOPHYSIOLOGY OF DEPRESSION: DO WE HAVE ANY SOLID EVIDENCE OF INTEREST TO CLINICIANS? *World Psychiatry*. 2010;9(3):155-161.
261. Hsiao JK, Potter WZ, Agren H, Owen RR, Pickar D. Clinical investigation of monoamine neurotransmitter interactions. *Psychopharmacology*. 1993;112(1):S76-S84. doi:10.1007/BF02245010
262. Kritzer MD, Peterchev AV, Camprodon JA. Electroconvulsive Therapy: Mechanisms of Action, Clinical Considerations, and Future Directions. *Harvard Review of Psychiatry*. 2023;31(3):101. doi:10.1097/HRP.0000000000000365
263. Cavanna AE, Robertson MM, Critchley HD. Catatonic Signs in Gilles De La Tourette Syndrome. *Cognitive and Behavioral Neurology*. 2008;21(1):34-37. doi:10.1097/WNN.0b013e318165a9cf
264. Pier MPBI, Hulstijn W, Sabbe BGC. Differential patterns of psychomotor functioning in unmedicated melancholic and nonmelancholic depressed patients. *Journal of Psychiatric Research*. 2004;38(4):425-435. doi:10.1016/j.jpsychires.2003.11.008
265. Walther S, Bernard JA, Mittal VA, Shankman SA. The utility of an RDoC motor domain to understand psychomotor symptoms in depression. *Psychological Medicine*. 2019;49(2):212-216. doi:10.1017/S0033291718003033
266. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR*. American Psychiatric Association Publishing; 2022.

267. Rutherford BR, Slifstein M, Chen C, et al. Effects of L-DOPA Monotherapy on Psychomotor Speed and [11C]Raclopride Binding in High Risk Depressed Older Adults. *Biol Psychiatry*. 2019;86(3):221-229. doi:10.1016/j.biopsych.2019.04.007
268. Rutherford BR, Choi J, Slifstein M, et al. Neuroanatomical Predictors of L-DOPA Response in Older Adults with Psychomotor Slowing and Depression: A Pilot Study. *J Affect Disord*. 2020;265:439-444. doi:10.1016/j.jad.2020.01.066
269. Starkstein SE, Petracca G, Tesón A, et al. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. *Journal of Neurology, Neurosurgery and Psychiatry*. 1996;60(3):326. doi:10.1136/jnnp.60.3.326
270. Lloyd JR, Silverman ER, Kugler JL, Cooper JJ. Electroconvulsive Therapy for Patients with Catatonia: Current Perspectives. *Neuropsychiatric Disease and Treatment*. 2020;16:2191-2208. doi:10.2147/NDT.S231573
271. Sackeim HA. Modern Electroconvulsive Therapy: Vastly Improved yet Greatly Underused. *JAMA Psychiatry*. 2017;74(8):779-780. doi:10.1001/jamapsychiatry.2017.1670
272. Salani D, Goldin D, Valdes B, DeSantis J. Electroconvulsive Therapy for Treatment-Resistant Depression: Dispelling the Stigma. *J Psychosoc Nurs Ment Health Serv*. 2023;61(6):11-17. doi:10.3928/02793695-20230222-02
273. Jakobson Mo S, Axelsson J, Jonasson L, et al. Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison. *EJNMMI Res*. 2018;8(1):100. doi:10.1186/s13550-018-0450-0
274. Marnier L, Korsholm K, Anderberg L, et al. [18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism. *EJNMMI Res*. 2022;12(1):56. doi:10.1186/s13550-022-00930-x
275. Sonni I, Fazio P, Schain M, et al. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. *Journal of Nuclear Medicine*. 2016;57(10):1529-1534. doi:10.2967/jnumed.115.171231

276. Veronese M, Santangelo B, Jauhar S, et al. A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach. *Neuropsychopharmacol.* 2021;46(6):1122-1132. doi:10.1038/s41386-020-00866-7
277. Trujillo P, Aumann MA, Claassen DO. Neuromelanin-sensitive MRI as a promising biomarker of catecholamine function. *Brain.* 2024;147(2):337-351. doi:10.1093/brain/awad300
278. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. *FEBS Letters.* 2002;510(3):216-220. doi:10.1016/S0014-5793(01)03269-0
279. Kashihara K, Shinya T. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. *Journal of Clinical Neuroscience.* 2011;18(8):1093-1096. doi:10.1016/j.jocn.2010.08.043
280. Isaias IU, Trujillo P, Summers P, et al. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. *Front Aging Neurosci.* 2016;8. doi:10.3389/fnagi.2016.00196
281. Kuya K, Shinohara Y, Miyoshi F, Fujii S, Tanabe Y, Ogawa T. Correlation between neuromelanin-sensitive MR imaging and 123I-FP-CIT SPECT in patients with parkinsonism. *Neuroradiology.* 2016;58(4):351-356. doi:10.1007/s00234-016-1644-7
282. Ryman SG, Poston KL. MRI biomarkers of motor and non-motor symptoms in Parkinson's disease. *Parkinsonism & Related Disorders.* 2020;73:85-93. doi:10.1016/j.parkreldis.2019.10.002
283. Cassidy CM, Zucca FA, Girgis RR, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. *Proceedings of the National Academy of Sciences.* 2019;116(11):5108-5117. doi:10.1073/pnas.1807983116
284. Depierreux F, Parmentier E, Mackels L, et al. Parkinson's disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI. *npj Parkinsons Dis.* 2021;7(1):1-10. doi:10.1038/s41531-021-00199-2
285. Cho SJ, Bae YJ, Kim JM, et al. Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its

heterogeneity: a systematic review and meta-analysis. *Eur Radiol.* 2021;31(3):1268-1280. doi:10.1007/s00330-020-07240-7

286. Ohtsuka C, Sasaki M, Konno K, et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. *Neuroscience Letters.* 2013;541:93-98. doi:10.1016/j.neulet.2013.02.012

287. Ohtsuka C, Sasaki M, Konno K, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. *Parkinsonism & Related Disorders.* 2014;20(7):755-760. doi:10.1016/j.parkreldis.2014.04.005

288. Wang L, Yan Y, Zhang L, Liu Y, Luo R, Chang Y. Substantia nigra neuromelanin magnetic resonance imaging in patients with different subtypes of Parkinson disease. *J Neural Transm.* 2021;128(2):171-179. doi:10.1007/s00702-020-02295-8

Figure legends

Figure 1 Anatomy and functional architecture of the striatum with relevant dopaminergic imaging findings in Parkinson's disease and depression. (A) Anatomical subdivisions of the striatum. (B) Neuroimaging findings corresponding to bradykinesia in Parkinson's disease. (C) Corticostriatal pathways and functional subdivisions of the striatum. (D) Neuroimaging findings corresponding to psychomotor retardation in depression. (A) The striatum is anatomically divided into the nucleus accumbens, caudate nucleus and putamen, the latter two being separated by the internal capsule. (B) A range of neuroimaging modalities implicate the striatum in the bradykinesia of Parkinson's disease and – where there is greater anatomical precision – studies have tended to emphasise the role of the putamen. (C) Most of the cortex projects to the striatum and there is some anatomical overlap in function, but in broad terms there is a dorsal-to-ventral gradient from sensorimotor striatum to associative striatum to limbic striatum. (D) Fewer studies have examined psychomotor retardation in depression, but there is converging evidence implicating the striatum, though less is known about the anatomical specificity within the striatum. Created in BioRender. Leong I. (2025) <https://BioRender.com/swnk7a0>.

Figure 2 Simplified representation of the dopamine synthetic pathway and radioligand action sites in a striatal dopaminergic synapse. In the final two steps of the dopamine (DA) synthetic pathway, tyrosine hydroxylase (TH) converts tyrosine to L-DOPA, which is subsequently converted into DA by aromatic L-amino acid decarboxylase (AAAD). DA is stored in vesicles for tonic and phasic release. The diffusion of DA across the synaptic cleft and its binding to post-synaptic DA D₂ receptors initiates intracellular cascades in the post-synaptic neuron that enable signal transmission. Following release, dopamine transporter (DAT) facilitate the reuptake of DA into the pre-synaptic neuron, which is then transported back into the vesicle by vesicular monoamine transporter type 2 (VMAT2). Selected PET/SPECT radioligands and their site of action are depicted: [¹⁸F]-FDOPA is taken up into the pre-synaptic dopaminergic neuron via an amino acid transporter, then decarboxylated by AAAD into fluorodopamine ([¹⁸F]-DA) and temporarily stored in vesicles. Thus, [¹⁸F]-FDOPA uptake can be interpreted as an indication of pre-synaptic DA synthesis and storage capacity. [¹¹C]-NMF uptake and [¹²³I]-FP-CIT binding indicate the reuptake capacity of DAT; [¹¹C]-raclopride and [¹²³I]-IBZM binding indicate post-synaptic D₂ receptor availability. Due to their competition with endogenous DA for binding, these radioligands can additionally derive an estimate of DA release by comparing ligand binding before and after a dopamine-stimulating event. DA — dopamine. TH — tyrosine hydroxylase. L-DOPA — L-3,4-dihydroxyphenylalanine/Levodopa. AAAD — aromatic L-amino acid decarboxylase. DAT — dopamine transporters. VMAT2 — Vesicular monoamine transporter type 2. [¹⁸F]-FDOPA — 6-[¹⁸F]Fluoro-L-3,4-dihydroxyphenylalanine. [¹⁸F]-DA — flurodopamine. [¹¹C]-NMF — S-¹¹C-nomifensine. [¹²³I]-FP-CIT — N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)tropane/¹²³I-Ioflupane. [¹²³I]-IBZM — Iodine-123-Iodobenzamide. Created in BioRender. Leong I. (2025) <https://BioRender.com/ng1ludyq>.

Table 1 Terminology used for concepts related to psychomotor retardation in neurology and psychiatry

Term	Selected conditions in which it is commonly described	Definition
Psychomotor retardation	Depression, schizophrenia ^{5,20}	Generalised slowing of movement and speech ²
Bradyphrenia	Parkinson's disease, Huntington's disease ²¹	Slowing of thought ²¹
Bradykinesia	Parkinson's disease, other parkinsonisms ²²	Slowed movement with a progressive reduction in amplitude or speed ²²
Hypokinesia	Parkinson's disease, Huntington's disease, other parkinsonisms ^{23,24}	A reduction in the quantity of movement ²⁴
Catatonica	Depression, schizophrenia, NMDA receptor encephalitis ^{25,26}	A syndrome involving signs of decreased, increased or abnormal psychomotor activity, including stupor, mutism and posturing ²
Akinesia	Akinetic mutism ^{24,a}	Absence of movement ²⁴

NMDA – N-methyl-D-aspartate.

^aAkinesia has sometimes been given a more liberal definition as a synonym for bradykinesia.²⁴

Table 2 Comparison of Shared Clinical Features between Parkinson's disease and Catatonia

	Parkinson's disease ^{48–51}	Catatonia ^{50,52–55}
Motor		
Rigidity	Present, especially cogwheel rigidity, increasing with activation	Often present, but tone may also be normal or reduced. Catalepsy is highly specific.
Hypokinesia (slowed or reduced movement)	Bradykinesia, akinesia	Stupor (decreased psychomotor movement and reactivity), akinesia
Tremor	Present at rest and postural	Not typically observed
Facial manifestations	Masked facies, reduced spontaneous blink rate	Flat affect, staring, reduced blink rate
Sudden motor freezing	Freezing of gait (sudden, unwanted inability to move) typically triggered by external stimuli	Motor blocking (<i>Sperrung</i> ; abrupt cessation in voluntary movement or speech), may not have external trigger
Non-motor		
Altered mental status	Depression, apathy, anhedonia, anxiety, psychosis, impulse control disorders	Depression, mania, anxiety, psychosis

Table 3 Summary of imaging findings by synaptic region

Condition	Pre-synaptic Findings		Post-synaptic findings	
	Tracer	Interpretation	Tracer	Interpretation
Parkinson's disease	↓ putaminal ¹⁸ F-FDOPA uptake ^{1–4} ↓ putaminal ¹¹ C-NMF binding ^{1,3} Positive correlation between putaminal ¹⁸ F-FP-CIT uptake and motor speed. ⁶	Reflects reduced pre-synaptic DA synthesis, storage and reuptake dysfunction Suggests reduced DA reuptake	Initial ↑ ¹²³ I-IBZM and ¹¹ C-raclopride binding in striatum contralateral to predominant motor symptoms; subsequent ↓ binding four years after onset ⁵	Initial ↑ D ₂ R density may be compensatory mechanism for pre-synaptic DA nerve terminal loss. Later ↓ density may reflect chronic under-stimulation.
Drug-induced Parkinsonism	↓ putaminal ¹²³ I-FP-CIT binding ⁷ ↓ putaminal ¹⁸ F-FDOPA uptake ⁸	Suggests intrinsic ↓ in DA synthesis, which may imply that drug-induced parkinsonism tends to occur in an at-risk population with subclinical pre-synaptic nigrostriatal dysfunctions in DA storage and reuptake ⁹	↓ putaminal ¹¹ C-raclopride binding ¹⁰	↓ D ₂ R binding, likely reflecting receptor occupancy by medications.
Neuroleptic malignant Syndrome	No studies to the authors' knowledge		Near absent basal ganglia ¹²³ I-IBZM binding in acute phase → near-normal binding despite persistent mild parkinsonian	Suggests high post-synaptic D ₂ R occupancy is a mechanism for akinesia

			symptoms after four months ¹¹	
Catatonia	↓ putaminal ^{12,13} and caudate ¹⁴ ¹⁸ F-FDOPA uptake Initial ↓ ¹²³ I-FP-CIT binding → Restored binding post-ECT/benzodiazepine treatment ¹⁵	↓ DA synthesis and storage. Reversible ↓ in DAT capacity.	No studies to the authors' knowledge	
Psychomotor retardation in depression	↓ left caudate ¹⁸ F-FDOPA uptake in PMR patients relative to HCs and non-PMR patients ¹⁶	↓ DA synthesis and storage in left caudate	Initial ↑ striatal ¹²³ I-IBZM binding pre-treatment compared to HCs and non-PMR patients; subsequent ↓ post-treatment in PMR patients relative to healthy controls and non-PMR patients ¹⁷ ↑ putaminal ¹¹ C-raclopride binding compared to HCs ¹⁸	Suggests either ↑ availability of D ₂ R due to ↓ synaptic DA levels, or a compensatory ↑ in D ₂ R density. Treatment may result in normalisation.

¹¹C-NMF = ¹¹C-nomifensine; ¹⁸F-FDOPA = ¹⁸F-dihydroxyphenylalanine; ¹²³I-FP-CIT = ¹²³I-N-3-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropine; ¹²³I-IBZM-SPECT = ¹²³I-iodobenzamide single photon emission computed tomography; D₂R = dopamine D₂ receptor; HC = healthy control.

Table 4 Comparison of diseases characterised by psychomotor retardation and response to dopaminergic medications

Condition	Levodopa	Dopamine Agonists	Dopamine Antagonists (Antipsychotics)	Other
Parkinson's Disease	Effective ¹⁹⁵	Effective ¹⁵³⁻¹⁵⁵	Deleterious ^{196,197}	Monoamine oxidase inhibitors are effective ^{156,158}
Neuroleptic Malignant Syndrome	Effective ^{168,a}	Bromocriptine is effective ^{166,167}	Causative ¹⁶⁴	-
Drug-induced Parkinsonism	Ineffective ¹⁹⁸⁻²⁰⁰	Rotigotine is effective ¹⁶²	Causative ¹⁶	Amantadine is effective ¹⁶¹
Catatonia	Effective ^{178-180,a}	Ineffective ^{201,a}	Controversial ²⁵ ; clozapine may be effective ¹⁷⁵	Methylphenidate is effective ^{181-183,a}
Depression with psychomotor retardation	Effective ^{187-189,a}	Effective ^{159,185,a}	Aripiprazole and quetiapine are effective ^{193,202,203}	Bupropion is effective ¹⁹¹

^aBased on limited evidence.




A Anatomical Subdivisions of the Striatum**B Bradykinesia in Parkinson's Disease****C Corticostriatal Pathways and Functional Subdivisions of the Striatum****D Psychomotor Retardation in Depression**

Figure 1
180x131 mm (x DPI)




Figure 2
184x76 mm (x DPI)

Efficacy made Convenient



TYSABRI SC injection with the potential to administer **AT HOME** for eligible patients*

Efficacy and safety profile comparable between TYSABRI IV and SC^{†,2}

[†]Comparable PK, PD, efficacy, and safety profile of SC to IV except for injection site pain.^{1,2}

**CLICK HERE TO DISCOVER MORE ABOUT
TYSABRI SC AND THE DIFFERENCE IT MAY
MAKE TO YOUR ELIGIBLE PATIENTS**

Supported by



A Biogen developed and funded JCV antibody index PML risk stratification service, validated and available exclusively for patients on or considering TYSABRI.



*As of April 2024, TYSABRI SC can be administered outside a clinical setting (e.g. at home) by a HCP for patients who have tolerated at least 6 doses of TYSABRI well in a clinical setting. Please refer to section 4.2 of the SmPC.¹

TYSABRI is indicated as single DMT in adults with highly active RRMS for the following patient groups:^{1,2}

- Patients with highly active disease despite a full and adequate course of treatment with at least one DMT
- Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gd+ lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI

Very common AEs include nasopharyngitis and urinary tract infection. Please refer to the SmPC for further safety information, including the risk of the uncommon but serious AE, PML.^{1,2}

Abbreviations: **AE:** Adverse Event; **DMT:** Disease-Modifying Therapy; **Gd+:** Gadolinium-Enhancing; **HCP:** Healthcare Professional; **IV:** Intravenous; **JCV:** John Cunningham Virus; **MRI:** Magnetic Resonance Imaging; **PD:** Pharmacodynamic; **PK:** Pharmacokinetic; **PML:** Progressive Multifocal Leukoencephalopathy; **RRMS:** Relapsing-Remitting Multiple Sclerosis; **SC:** Subcutaneous.

References: 1. TYSABRI SC (natalizumab) Summary of Product Characteristics. 2. TYSABRI IV (natalizumab) Summary of Product Characteristics.

Adverse events should be reported. For Ireland, reporting forms and information can be found at www.hpra.ie. For the UK, reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or via the Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Biogen Idec on MedInfoUKI@biogen.com 1800 812 719 in Ireland and 0800 008 7401 in the UK.